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SUMMARY 
In this work four nanoparticle systems were designed: two 
for medical and two for industrial applications. 
The purpose of the first part of my study concerns 
the manufacture of a NPs-enzyme system for cancer 
therapy: Fe3O4 NPs@APTES-DAAO. This system combines 
the magnetic properties of iron oxide nanoparticles 
(Fe3O4 NPs) with the ROS generating enzyme D-amino 
acid oxidase (DAAO), in order to efficiently direct the 
enzyme into the tumor and kill tumor cells. Under our best 
experimental condition, we have immobilized 100% of 
the enzyme in term of activity and quantity. The system 
showed an activity of 7U/mg of NPs and an apparent Km 
for D-Ala similar to that of the free enzyme. In vitro 
cytotoxicity demonstrates the higher efficacy of the 
system in respect to free enzyme. In vivo experiments did 
not have highlighted adverse side effects of Fe3O4 
NPs@APTES-DAAO at a concentration of 20mg/kg. At the 
tested concentrations our NPs do not pass brain-blood 
barrier and do not accumulate in the heart.  
The second medical system designed consists in 
magnetic iron oxide nanoparticles conjugated with the 
antibiotics teicoplanin. Similar to the previous system, 
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Fe3O4 NPs@Teicoplanin takes advantage of the 
magnetic character of NPs for a specific targeting of the 
antibiotic. Teicoplanin has been conjugated on Fe3O4 
NPs@CMCS with efficiency in term of quantity over the 
90%. Unfortunately, the reaction was not reproducible 
and some problems are associated with storage. The 
main problem is probably due to the wide active site of 
teicoplanin: interactions with NPs may affect some of the 
residues involved in substrate recognition, leading to a 
loss of activity. The optimization of reaction conditions, by 
protecting the active site, might solve the problem. 
The first system for industrial application is 
composed by Fe3O4 NPs and the enzyme cephalosporin 
C acylase (VAC). Despite the efficiency of VAC 
conjugation on NPs (90%), the low specific activity of the 
enzyme does not allow to obtain en efficient system on 
an adequate support (24mg of NPs for 0.48U if VAC). 
Moreover bioconversion analysis indicates that Fe3O4 
NPs@APTES interfere with the assay. For this reason there is 
the need to find other methods to assess the 
bioconversion ability of the enzyme (for example by 
HPLC). In order to make the system more efficient, future 
efforts will be aimed at finding a VAC mutant with a 
higher specific activity, in order to increase the specific 
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activity of the system. 
The last enzyme system for industrial application 
designed in this study is composed of Fe3O4 NPs 
conjugated to L-aspartate oxidase (LASPO). LASPO was 
conjugated on Fe3O4 magnetic NPs with efficiency in 
term of unit of 60%. 1U of enzyme was conjugated on 
216mg of NPs. The system was efficiently used for the 
resolution of a racemic mixture of D,L-aspartate: 1U 
converts 250mM of D,L-aspartate in 240min. Moreover 
Fe3O4 NPs@APTES-LASPO seems to have a stable activity 
in a wide pH range (8-10), with an optimum around pH 9. 
Thanks to the high stability of the system it was possible to 
use Fe3O4 NPs@APTES-LASPO for several cycles of 
bioconversion. This is a great advantage and makes 
Fe3O4 NPs@APTES-LASPO an excellent system for the 
resolution of racemic solution of D,L-aspartate. 
 
  
Chapter I - INTRODUCTION  
 
 
 
 
 
 
 
 
 
CHAPTER I 
INTRODUCTION 
 
I.I BACKGROUND 
 
Chapter I - INTRODUCTION Pag. 1 
 
I.I. BACKGROUND 
I.1 NANOTECHNOLOGY AND NANOPARTICLES 
In recent years, nanoparticles (NPs) and other 
nanomaterials have permeated essentially all areas of 
our everyday lives. In industrial applications, they have 
become indispensable components of catalysts [1], 
sensor [2] and photovoltaic devices [3]. In the 
biomedical field, they have found widespread use as 
nanovaccines [4], nanodrugs [5] and diagnostic imaging 
tools [6]. 
Nanostructures and nanosystems are of great interest 
beyond the simple scaling down of larger structures. 
Among the countless motivations for nano-research, the 
most important is that nanoscale systems have peculiar 
properties. When an object is scaled, the volume 
changes by the said scale cubed, and the surface area 
changes by that scale squared. In fact, the surface area 
and volume of a cube and of a sphere respectively can 
be found with the following equations: 
S=6l2 and V=l3   S=4πr2 and V= (4πr3)/3 
The growth in volume is always greater than the increase 
in surface area. This is true for cubes, spheres, or any 
other object whose size is augmented without changing 
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its shape. This means that the surface area to volume 
ratio increases by the scaling factor as the system scales 
down (a radius diminution by a factor of 1 million 
corresponds to a growth of the surface area to volume 
ratio by a factor of 106).  
There are also effects that occur for reasons other than 
the strict scaling law effects mentioned. For example, as 
a spherical particle gets progressively smaller the 
curvature of the surface increases. This is notable 
because surface curvature can affect certain types of 
physical interactions (see paragraph I.4). This effect is not 
strictly a nanoscale effect but a conformal one, where 
the surface curvature is the key to the result. A study 
recently showed that gold particles within a certain size 
range would disrupt cell membranes and cause 
cytotoxicity [7, 8].  
I.2 MAGNETIC NANOPARTICLES 
Nanoscale materials are very fascinating also because 
their magnetic properties differ substantially from the bulk 
counterparts, due to the increasing role of the surface 
spins as the particle size is diminished. Moreover at the 
nanoscale level, magnetic-like behavior could appear in 
materials that do not have magnetic behavior in the bulk 
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[9]. Thus nanomaterials are attracting a great deal of 
interest due to their potential uses in different magnetic 
disciplines such magnetic recording [10, 11, 12], 
magnetic resonance imaging and related technologies 
[13, 14, 15], analytical chemistry [16]. 
Among magnetic nanoparticles, of great concern are 
Superparamagneric Iron Oxide Nanoparticles (SPIONs) 
whose research has been growing exponentially over the 
last several years. The field continues to drive in the 
direction of biomedical applications, by exploiting the 
immense qualities of IONs [17]. SPIONs belong to the class 
of inorganic based particles having an iron oxide core, 
coated by either inorganic materials (silica, gold) or 
organic materials (phospholipids, fatty acids, 
polysaccharides, peptides or other surfactants and 
polymers). In contrast to other nanoparticles, their 
magnetic properties, based on their inducible 
magnetization, allow them to be directed to a defined 
location and/or heated in the presence of an externally 
applied magnetic field [18]. 
Among all iron oxides, magnetite Fe3O4 possesses the 
most interesting properties because of the presence of 
iron cations in two states, Fe2+ and Fe3. Up to date Fe3O4 
NPs have found applications in several biomedical field 
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[19], being the only one magnetic NP approved by FDA 
[20]. These particles are chemically very active and can 
oxidize when exposed to air. Fe3O4 NPs oxidation result in 
a partial loss of the magnetic character, thus it is 
necessary to create a coating for stabilizing the particles 
[21]. In some cases, the coating merely acts as a barrier 
protecting the NPs against external agents, but in other 
cases it can drastically affect the electronic properties of 
the NPs. The modification of the NP surface by means of 
bonding specific molecules to the surface atoms plays a 
crucial role in the minimization of the energy and, 
consequently, in the stabilization of the system. This 
modification can also act as a support for a further 
functionalization of NPs with molecules of interest [22]. 
I.3 FUNCTIONALIZATION OF NANOPARTICLES  
Three types of structure can be identified when NPs are 
coated: core-shell, matrix and shella-core-shellb (figure 1). 
 
Fig. 1: Different structures for coated NPs [21]. 
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- The first consist of a core of iron oxide NPs coated by 
any sort of material including organic ones. 
- Matrix includes two structures: mosaic and shell-core. 
In the first one the shell layer, made of organic 
molecules, is coated to a lot of uniformly IONPs. The 
second one consists of an organic compound NPs 
core and IONPs shells connected with the organic 
core by the interaction of chemical bound. 
- In the shella-core-shellb structure, a shell layer made 
of organic molecules is coated to shell-core 
structurally functionalized IONPs [21]. 
There are two strategies for introducing functional groups 
to surfaces and NPs (figure 2).  
 
Fig. 2 Two different types of NP functionalizations 
[23]. 
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The first method is direct functionalization, where the 
whole functional ligand is a bi-functional organic 
compound. In this approach, one of the functionally 
reactive groups is used to attach to the NPs surface 
(complexing agent) and the second group contains the 
required active functionality (NP surface modifying 
group). The second method is post-functionalization, 
which is generally preferred because of its versatility and 
because the nature of the functionalizing moieties may 
not be fully compatible with the NP synthesis conditions. 
The functionalizing moiety is a bifunctional compound 
where a binding chelating group is reacted first and the 
group of coupling site can be converted, in a second 
step, to the final functional group. Post-functionalization 
of the particles requires a molecule to be grafted on the 
surface, producing a structure that can be described as 
N-C-F (Nanoparticle-Chelating agent-Functional group). 
For post-functionalization, silane-like compounds have 
been generally used [23]. 
Among silane compound of great interest is 3-
Aminopropyltriethoxysilane (APTES, figure 3) [24]: 
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Fig. 3 APTES structure. APTES hydrolysis in water 
and subsequent condensation to form silane 
polymer. Silane polymer reacts with NPs. 
When APTES is in water, it hydrolyzes and condensates to 
form a silane polymer. In the hydrolysis reaction, alkoxide 
groups –OC2H5 are replaced by hydroxyl groups (OH) to 
form reactive silanol groups, which condense on the one 
hand with other silanol groups to produce siloxane bonds 
(Si–O–Si) and on the other hand with -OH on the NPs 
surface to produce NP-O-Si bonds. NH2 groups remain 
free for further bonds with other molecules [25]. 
Another very common polymer for functionalization is 
chitosan and its derivatives. Chitosan is a natural 
macromolecule consisting of β-1,4-linked 2-amino-2-
deoxy-D-glucopyranose and is derived by N-
deacetylation of chitin in aqueous alkaline medium. 
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Since it is a well-known biocompatible, biodegradable 
and low-toxicity biomaterial, many applications of 
chitosan have been developed in the biomedical and 
tissue engineering fields [26]. However chitosan with high 
degree of acetylation is insoluble in water because of 
the strong intermolecular hydrogen bonding (H-bond). 
Nevertheless, some modifications on the –OH and –NH2 
position of chitosan can be done to improve its water 
solubility. Among the numerous water-soluble chitosan 
derivatives, o-carboxymethylchitosan (OCMCS) is the 
most promising (figure 4) [27].  
 
Fig. 4 Chitosan and its derivate o-
carboxymethylchitosan monomers [27]. 
Moreover, also OCMCS can act as a support for further 
NPs functionalization with molecules of interest, creating 
a core-shell system for any application [28]. In this study 
post-functionalization method was used for all NPs 
produced.  
I.I BACKGROUND 
 
Chapter I - INTRODUCTION Pag. 9 
 
In core-shell particles, the shell thickness can be tuned to 
provide the binding of biomolecules for the purpose of 
targeted drug delivery, bio-sensing or whatever 
application needed, creating a multifunctional particle 
as shown in figure 5 [29].  
 
Fig. 5 Scheme of multifunctional nanoparticle for 
molecular imaging, drug delivery and therapy. 
Optionally functionalized and devised 
nanoparticles could be achieved for 
individualized diagnosis and treatments [28]. 
I.4 NP INTERACTIONS 
NPs, either naked or functionalized, may invade the 
human body via inhalation, ingestion or through the skin. 
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Once they have entered a biological milieu, NPs will 
inevitably come into contact with a huge variety of 
biomolecules that are dissolved in body fluids (interstitial 
fluid between cells, lymph or blood). These biomolecules 
immediately coat NPs and form the so-called ‘corona’, 
which determines the biological identity of the NP. The 
great majority of these molecules are protein. The 
composition of the corona is dynamic and depends on 
the relative concentrations of the individual components 
and on their affinities toward the NP surface (figure 6) 
[30]. 
 
Fig. 6 NPs enter the human body via different 
way. In extracellular fluids NPs are coated with 
the protein corona and come into contact with 
cell membrane, entering cells by active or 
passive uptake [30]. 
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Corona composition varies also according to NP size and 
shape. As surface changes from flat to spherical and as 
the particles become smaller, the composition and 
organization of associated protein will change 
dramatically. Indeed, highly curved surfaces can 
suppress protein adsorption to the point where it no 
longer occurs. As already said, the protein corona is a 
dynamic identity, so it is important to highlight that it is 
not just the composition and organization of this protein 
layer, but the exchange times of the protein on the 
nanoparticles that is “read” by cells. Moreover the 
exchange process is important when particles 
redistribute from one compartment or organ to another, 
such as upon uptake into cells from the bloodstream, or 
upon transport from the cytosol to the nucleus [31]. 
Once entered the human body, NPs have to surmount 
the cell membrane. Large macromolecular 
agglomerates, protein assembles, virus and also NPs are 
encapsulated in vesicles and selectively transported into 
and out the cell via endo- or exocytosis. Different types 
of endocytosis mechanisms are known (figure 6), but 
regardless of the specific internalization mechanism, the 
cell-NPs interactions are, on the one hand, modulated by 
physicochemical properties of the NPs including size, 
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shape, surface charge and surface chemistry [32] and, 
on the other hand, by cell-specific parameters such as 
cell type or cell cycle phase [33]. 
A size-dependent uptake in different cell lines has been 
observed for Au [34, 35, 36], mesoporous silica [37], 
polystyrene [38] and iron oxide NPs [39], with the 
maximum cellular uptake at a NP core size in the range 
of 30–50 nm, which suggests that there is an optimal size 
for active uptake. The size-dependent interaction of NPs 
with the cell membrane is likely related to the 
membrane-wrapping process that initiates receptor-
mediated endocytosis. Small NPs have less ligand-to-
receptor interactions than larger ones; thus, several small 
NPs need to interact simultaneously with receptors in 
close proximity to trigger membrane wrapping. In 
contrast, an individual large NP can act as a cross-linking 
agent to cluster receptors and induce uptake. 
Thermodynamically, a 50-60 nm NP is capable of 
recruiting enough receptors to successfully trigger 
internalization. The nature of the protein corona, which is 
controlled by the NP surface ligands, may also affect the 
membrane response and, thereby, modify the cellular 
responses toward the NPs [40, 41].  
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The size, as well the coating, can also influence the 
subcellular distribution of the internalized NPs. Lovrić et al. 
demonstrated that positively charged 5.2-nm CdTe QDs 
were distributed throughout the cytoplasm of N9 cells but 
did not enter the nucleus, whereas positively charged 
2.2-nm QDs were localized predominantly in the nuclear 
compartment [42]. 
Once inside a cell or tissue, the surface layer, including 
the adsorbed biomolecules, and also the NP core 
material will likely be metabolized. Subsequently, the 
organism may excrete the remnants of the NPs. These 
processes are again dependent on the physicochemical 
properties of NPs including their size [43]. 
All these interactions with the biological environment can 
trigger toxicity (figure 7). Smaller NPs appear to be more 
toxic than larger ones. Small NPs possess a high surface 
area relative to their total mass, which increases the 
chance to interact with surrounding biomolecules and, 
as a consequence, to trigger adverse responses. Surface 
functionalization also plays important roles. For example, 
cationic NPs are considered more toxic than neutral or 
anionic ones, possibly due to their high affinity towards 
the negatively charged plasma membrane. 
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Fig. 7 NPs may interact with membrane bound 
cellular receptor and, after internalization, with 
pathways inducing cell responces and maybe 
citotoxic effect [30]. 
In conclusion the size, shape, surface functionalization 
and chemistry of NPs has a strong effect on their 
interactions with living cells, influencing uptake 
efficiency, internalization pathway selection, intracellular 
localization and cytotoxicity [30]. 
I.5 APPLICATIONS 
Although nanotechnology is a relatively new branch of 
science, it has found a large use in many fields. The 
potential of engineered sub-micron structures, which are 
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comparable in size to biological molecules, has been 
recognized ever since the 1950s. However, the rapid 
development of applied nanotechnology only began in 
the 1990s following the discovery of the Nobel Prize-
winning technique scanning tunneling microscopy and, 
several years later, atomic force microscopy [44]. Both 
these methods, which allow the visualization and 
handling of small-scale physical matter with exceptional 
accuracy, triggered an exponential growth in 
nanoscience. By the year 2000, nanotechnology was 
universally recognized as a landmark innovation, and 
named the sixth truly revolutionary technology 
introduced in the modern world [45]. In response to the 
widespread practical applications of nanotechnology, 
many countries have introduced specialized courses in 
nanoscience as part of high school, undergraduate and 
graduate curricula, and promoted dedicated 
international research initiatives [46]. Over the last 
decade, nanotechnology has been extensively 
introduced into biological, medical and industrial 
applications [47]. Estimates suggest that the number of 
nanotechnology patents, related only to healthcare, has 
increased from less than 200 in the year 2000 to nearly 
10,000 by the year 2010, doubling almost every three 
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years and thus reflecting the rapid expansion of this 
pioneering industry [48].   
Among the most recent applications could be included 
those concerning water purification, wastewater 
treatment [49], environmental remediation [50], food 
processing and packaging [51], agriculture production 
and crop protection [52]. The majority of applications in 
these areas have focused on the nanomaterials for 
improved efficiency and productivity. 
I.5.1 MEDICAL APPLICATIONS 
Nanoparticles used in biomedical applications include 
liposomes, polymeric micelles, inorganic and polymeric 
nanoparticles, nanorods and quantum dots. All have 
been tested pre-clinically or clinically for targeted 
drug/gene delivery or as agents to enhance diagnostic 
imaging output like in MRI [53]. Other nanoparticles, like 
water-soluble synthetic polymers (dendrimers), were 
tested in pre-clinical models for the delivery of drugs, 
genes and as imaging agents, showing a rich versatility 
for tailoring their binding properties to several 
requirements, among them facilitation of cellular uptake 
of drugs (e.g. cancer drugs) [54, 55]. 
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On-going improvement in the safety of biomedical 
nanomaterials, along with the accumulation of 
experimental evidence supporting the benefits of 
nanomaterial-based agents in terms of selectivity, 
sensitivity, affinity and detection limits, has led to the 
expansion of nanobiotechnological tools in a number of 
applications (such as cardiovascular, neurological 
gastrointestinal, autoimmune inflammatory, infectious 
and, reproductive diseases). Nevertheless, traditionally, 
the main scope of nanobiotechnology lies in the field of 
cancer diagnostics and treatment, with the aim to select 
and destroy affected cell populations with ultimate 
precision [44].  
NANOONCOLOGY  
The impact of nanobiotechnology on oncology (shown 
schematically in figure 8) is huge and includes fields 
ranging from discovery of tumor biomarkers to 
development of devices for cancer surgery [56]. In 
particular, drug-delivery is the most explored field, which 
aims to design carriers that deliver drugs more precisely 
to tumor cell and maintain them at a therapeutic 
concentration over a long period. Besides considerable 
progress in cancer therapy and the many anticancer 
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drug approved and in phase II clinical trials 
(http://www.cancer.gov/CLINICALTRIALS), treatment of 
cancer still has a lot of side effects [57]. For this reason 
nanoparticles could be an efficient alternative to 
conventional tumor therapies, serving as systems 
capable of enhancing efficacy, while simultaneously 
reducing side effects. 
 
Fig. 8 Role of Nanobiotechnology in the 
management of cancer [56]. 
There are two cancer specific physiological strategies: 
passive targeting by Enhanced Permeability and 
Retention (EPR) effect or active targeting. The first 
strategy takes advantage of the peculiar physiology of 
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tumor in respect of normal tissue. Tumor presents an 
enhanced permeability of vessels with a little lymphatic 
drainage, leading to a passive accumulation and 
retention of NPs with prolonged circulation times (EPR 
effect). 
The second strategy may exploit molecular binding 
receptor or magnetic guidance. NPs, in fact, on the one 
hand can be modified with surface markers that enable 
their specific recognition by target cells, facilitating 
effective delivery in the tumor tissue. On the other hand, 
magnetic NPs can be functionalized with anticancer 
drug and guided along an externally placed magnet 
into the tumor. Moreover, magnetic NPs produce heat 
through various energy losses under an external 
alternating magnetic field, causing cancer destruction 
by activating cell-death signaling (hyperthermia) [58]. 
Many works have been published in the literature in this 
regard [59-63]. 
I.5.2 INDUSTRIAL APPLICATIONS 
Maybe more than in medicine, nanotechnology has 
expanded in industrial area, where, by now, NPs are 
used in almost each field. Table 1 gives an overview of 
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industrial market segment based on nanoparticulate 
material (table 1). 
 
Table 1 Overview of material based on 
nanotechnology in different areas [64]. 
Nanotechnology has aroused much interest particularly 
in enzyme biocatalysis, where nanomaterials can 
provide the upper limits on enzyme-efficiency-
determining factors [65].  
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ENZYME BIOCATALYSIS  
Enzymes are versatile biocatalysts and are useful in many 
areas of research, including organic synthesis, 
immunoassays, and substrate sensing. The specific 
chemo-, regio-, and stereoselectivity of enzyme-
mediated transformations remarkably demonstrate their 
superiority compared to chemical catalytic reactions 
[66]. However, the use of free enzymes shows some 
significant drawbacks, such as thermal instability, 
susceptibility to attack by protease, activity inhibition, 
high sensitivity to several denaturing agent and the 
impossibility of separating and reusing free catalysts at 
the end of reaction. 
Among the countless procedure for circumventing these 
constrains and improve enzyme stability, enzyme 
immobilization is the most worthy. Immobilized enzymes 
have the advantage of a larger pH range and better 
thermal stability, in addition to an easy separation from 
the solution. Immobilized enzymes have the advantage 
of being easily removed from the bioreactor and 
replaced when they lose their activity. Other advantages 
are enhanced enzyme activity, modification of substrate 
selectivity/enantioselectivity and multienzyme reaction 
[67, 68]. Moreover many biomolecules, such as 
I.I BACKGROUND 
 
Chapter I - INTRODUCTION Pag. 22 
 
membrane proteins, perform their specific biorecognition 
or biocatalytic events while immobilized on the surfaces 
of cells or organelles; hence also these enzymes take 
advantage of their immobilization.  
Several synthetic scaffolds and supports, including gels, 
macromolecules, planar surfaces, and nanocomposites, 
have been used to immobilize enzymes. Among them, 
NPs provide an almost ideal mix of properties (minimal 
diffusional limitation, maximum surface area and high 
effective enzyme loading) to optimize the performance 
of immobilized enzymes, while harnessing the fluorescent, 
magnetic and interfacial behavior of the resulting 
nanomaterial [69]. Compared with enzymes immobilized 
on micrometric supports, a nanobiocatalyst could 
achieve a much higher enzyme loading capacity and 
significantly enhanced mass transfer efficiency [70]. 
Magnetic NPs have received increasing attention due to 
their distinct properties such as ease of surface 
modification and magnetic character, which facilitate 
the recovery using a magnetic field [66]. Among 
magnetic NPs, Fe3O4 NPs have recently emerged as 
promising supports for immobilization because they are 
cheap and biocompatible. In particular, Fe3O4 
nanoparticles coated with a thin layer of silica have 
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beneficial properties, such as invariant catalytic activity 
and stability [71]. 
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I.II NANOPARTICLE SYSTEMS FOR MEDICAL 
APPLICATIONS 
II.1 ANTITUMOR SYSTEM: Fe3O4 NP@DAAO 
The purpose of the first part of my study concerns the 
manufacture of a magnetic NPs system for cancer 
therapy. The system is proposed as a broad spectrum, 
low cost and potentially able to cross biological barriers 
(such as the blood-brain barrier) alternative to 
conventional tumor therapies. It is composed of 
magnetic iron oxide NPs conjugated with the ROS 
generating enzyme D-aminoacid oxidase (DAAO). Fe3O4 
NP@DAAO wants to combine the advantages of 
magnetic NPs (low-toxicity, specific target by a 
magnetic field, ability to cross biological barriers) with 
those of DAAO (no-toxicity, easy modulation of the 
activity, hence of ROS generation). The system can be 
i.v. Injected and addressed by an external magnetic 
field in the tumor area. Here D-amino acids (naturally 
present or externally injected) act as substrate for the 
enzyme, causing H2O2 production and tumor cell death 
by apoptosis (figure 9). 
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Fig. 9 Schematic representation of Fe3O4 
NPs@DAAO antitumor system. 
II.1.1 DAAO 
DAAO is a flavoenzyme and catalyzes the 
dehydrogenation of D-amino acids to yield a-imino 
acids and, upon subsequent hydrolysis, a-ketoacids and 
ammonia. Oxygen, the terminal redox acceptor, 
reoxidizes the reduced FAD cofactor to give hydrogen 
peroxide [72]. 
  
Fig. 10 Scheme of the reaction catalyzed by D-
amino acid oxidase [73]. 
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This flavoxidase was discovered in 1935 by Krebs and all 
the chemical aspects of the enzyme reactivity were 
described in detail between 1950 and 1990, using the 
protein purified from pig kidney (pkDAAO) that for many 
years represented the only DAAO available in fairly good 
amounts and in a homogeneous form. Starting in the 
mid-1980s, other DAAO proteins became available, 
especially from the microorganisms (Rhodotorula gracilis, 
RgDAAO and Trigonopsis variabilis, TvDAAO) and, few 
years ago, even human DAAO (hDAAO) was cloned.  
Putative DAAO genes have been identified in all 
kingdoms; the main exception is represented by plants, 
in which a DAAO was purified only from the alga 
Chlorella vulgaris. DAAO is present in prokaryotes and is 
almost ubiquitous in eukaryotic organisms, from the 
simplest such as fungi, through fish to mammals, where it 
is present mainly in the kidney, liver and brain [73]. 
DAAO IN PROKARYOTES 
In prokaryotes there is a flavoenzima called D-amino 
acid dehydrogenase (DAAdH), which oxidizes D-amino 
acids into the corresponding α-ketoacids. DAAdH in 
E.coli is a heterodimer composed of two subunits of 45 
and 55 kDa; the smallest contains FAD as a coenzyme. It 
seems to be a peripheral membrane protein, associated 
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with the inner membrane of the cell and appears to 
have a dual role: it permits the bacteria growth (allowing 
the use of D-amino acids as a source of energy) and it 
prevents the local concentration of amino acids, which 
could have an inhibitory effect on bacteria growth [74]. 
DAAO IN EUKARYOTES 
In eukaryotic microorganisms, such as fungi, DAAO is a 
peroxisomal enzyme. This location allows an efficient 
removal of the toxic hydrogen peroxide produced 
during the reaction.  
RgDAAO is a very stable homodimer; each subunit binds 
a FAD non-covalently. The primary structure of RgDAAO 
comprises from 345 to 368 amino acids, corresponding 
to a molecular mass of 40076 Da for monomer [73]. 
 
Fig. 11 Monomer-monomer interaction, head-to-
tail, in R. gracilis. The thick arrows identify the 
βF5-βF6 loop and the thin arrows identify the α-
helices αI3 and aI3 [73].  
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The secondary structure consists of 11 α-helices and 13 β-
sheets. The N-terminus contains the dinucleotide-binding 
domain characterized by a motif βαβ. The whole 
cofactor is buried inside the protein. The C-terminus 
contains a long loop of 21 amino acids (not present in 
other known DAAO sequences), which is involved in the 
head-tail dimerization. The active site of RgDAAO is a 
cavity delimited by the two long β-strands I4 and I8 bent 
around the isoalloxazine ring of the flavin and the two 
short β-strands I5 and I6 situated close to the substrate-
binding site. The flavin forms the “bottom” of the cavity. 
All these β-strands have an antiparallel orientation and 
are connected to each other by H-bonds resulting in a 
rather rigid arrangement [75]. 
DAAO BIOLOGICAL ROLE IN EUKARYOTES 
The biological role of the D-amino acid oxidase is to 
metabolize D-amino acids, which are derived from 
exogenous and endogenous sources. D'Aniello and 
colleagues in 1993 showed that about 80% of D-amino 
acids in the diet is metabolized by the organism. The D-
amino acids once oxidized in the corresponding α-
ketoacids, can be on the one hand converted into L-
amino acids and integrated into the proteins, on the 
other hand used directly for the metabolism. If the D-
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amino acids are not metabolized, accumulate in tissues 
and cause extensive damage [76]. Accumulation of D-
amino acids in mammals is one of the characteristics of 
aging; accumulation of D-aspartate was observed in the 
white matter of the human brain. Recently it was also 
found that DAAO has a very important role in 
maintaining adequate levels of D-serine in different brain 
tissues. D-serine is an important regulator of the receptors 
N-methyl-D-aspartate (NMDA) which dysfunction, due to 
erroneous DAAO gene expression, is one of the possible 
causes of schizophrenia. Finally, it was found a lower 
activity of DAAO in tumor cells of kidney and liver 
compared to the healthy ones and therefore this 
parameter could be used for early tumor detection in 
these organs [77]. 
INDUSTRIAL AND MEDICAL APPLICATIONS OF RGDAAO 
The most important industrial application of DAAO is the 
enzymatic deamination of cephalosporin C to 7-(5-
oxoadipoamido) cephalosporanic acid, a key 
intermediate for the production of semisynthetic 
cephalosporins. This reaction without the use of DAAO 
would be very laborious and expensive, so this enzyme 
allows a faster and cheaper production of semisynthetic 
cephalosporin antibiotics. Among all DAAOs, RgDAAO is 
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preferred because of its high turnover rate and FAD 
binding stability [78]. 
In the medical field the DAAO can be used for the 
production of α-ketoacids, these are used as a food 
additive for patients with chronic uremia. Moreover, the 
production of hydrogen peroxide by DAAO immobilized 
on a support can be used for the tumor treatment. 
DAAO AND TUMORS 
DAAO may be regarded as a promising anticancer 
therapeutic whether used in protein therapy [79], gene 
therapy [80] or as a ROS generating enzyme. In this last 
case DAAO may act as angiogenesis inhibitor in 
combination with other factor like 3-bromopyruvate and 
citrate [81], or as an apoptosis enhancer by production 
of H2O2 [82]. In this regard many ROS generating enzyme 
have attracted interest in the past, like glucose oxidase 
(GO) or xanthine oxidase (XO). However, regulation of 
ROS production is critical. Exogenous administration of 
GO substrate (oxygen and glucose) is problematic 
because the availability of its substrates cannot be 
significantly modulated.  
Similarly XO production of superoxide cannot be 
regulated in vivo, because it is a promiscuous enzyme 
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with a wide range of ubiquitous substrates. DAAO, on 
the contrary, is an optimal candidate for ROS generating 
therapy, because D-amino acid are poorly present in 
human organism and the stereoselectivity of 
Rhodotorula gracilis DAAO appears to be absolute. Thus, 
production of ROS by RgDAAO in tumor cells could be 
regulated by exogenous administration of D-amino 
acids [83].  
II.2 ANTIBACTERIAL SYSTEM: NP@TEICOPLANIN 
This medical system is composed of magnetic iron oxide 
nanoparticles (Fe3O4) conjugated with the antibiotics 
teicoplanin. Similar to the previous system, 
NP@Teicoplanin wants to takes advantage of the 
magnetic character of NP for a specific targeting of the 
antibiotic.  
II.2.1 ANTIBIOTICS CONCERN 
Pathogenic bacteria remain a major health concern, 
because they are responsible of a large number of 
deaths and hospitalizations each year. Despite the great 
progress in antimicrobial development, many infectious 
diseases, especially intracellular infections, remain 
difficult to treat. One major reason is that many 
antimicrobials are difficult to transport through cell 
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membrane and have low activity inside the cells, thereby 
imposing negligible inhibitory or bactericidal effects on 
the intracellular bacteria. In addition, antimicrobial 
toxicity to healthy tissue poses a significant limitation to 
their use [84]. Moreover bacteria are gaining resistance 
at an alarming rate, that is why new therapeutic are 
necessary. A range of potential solutions has been 
researched and a large group of these studies includes 
the implementation of nanotechnologies and 
nanomaterials to create new antibacterial 
nanomedicines that increased effectiveness and 
efficiency [84]. The first advantage produced by NPs is 
the reduction of antibiotic dose. Usually for therapeutic 
purpose, the amount of antibiotics often given for the 
treatment is much higher than the dose required for 
killing the pathogens. It has been reported that ampicillin 
loaded NPs, used for the treatment of salmonella 
infection in mouse, reduce the drug by 40 folds 
compared to free ampicillin [85]. Moreover, in some 
cases the activity of the antibiotic result enhanced by 
linkage to or in combination with NPs [86, 87, 88]. This is 
very important because recently has emerging 
resistance to the so-called “last-resort drugs” such as 
vancomycin and teicoplanin, which are typically used to 
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treat infection by pathogens that resist more commonly 
used antibiotics. Immobilization of these antibiotics on NP 
may be a very important innovation able to solve 
resistance emergency [89].  
II.2.2 TEICOPLANIN 
Teicoplanin from Actinoplanes teichomyceticus is a 
glycopeptide antibiotic of the vancomycin family. It 
binds to the D-Ala-D-Ala terminus on the cell wall of 
gram-positive bacteria by hydrogen bonding, thereby 
preventing enzyme-mediated crosslinking of 
peptidoglycan and eventually leading to cell death.  
 
Fig. 12 Structure of teicoplanin from 
Actinoplanes teichomyceticus. Atoms involved 
in hydrogen bond with substrate are marked in 
yellow. 
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Although it is not routinely used in hospitals, teicoplanin is 
more active than vancomycin against Staphylococcus 
species, including methicillin-resistant strains. Teicoplanin 
has fewer side effects and exhibits a longer half-life in 
humans [90]. Teicoplanin binds its cell-wall peptide target 
with higher affinity than vancomycin and most other 
glycopeptide antibiotics. Teicoplanin interact with its 
ligand as a monomer, rather than a back-to-back dimer 
as vancomycin does; nevertheless teicoplanin is 
speculated to recognize its ligand in the same manner as 
vancomycin via five hydrogen bonds (figure 13). 
 
Fig. 13 Diagrammatical representation of the 
interactions between a peptide ending in –D-
Ala-D-Ala and the aglycone of a glycopeptide. 
 I.II NANOPARTICLE SYSTEM FOR MEDICAL APPLICATION  
 
Chapter I - INTRODUCTION Pag. 35 
 
Teicoplanin adopts a curved conformation, with the N- 
and C-terminus of the antibiotic closing around the 
target peptide to form a concave binding pocket. The 
mannose attached to amino acid 7 at the C-terminal 
end of the antibiotic interacts with a hydroxyl group on 
the side chain of amino acid 1 at the N-terminal end of 
the molecule, forming a hydrogen bond; the side chains 
of amino acids 1 and 7, together with the mannose, form 
the floor of the ligand-binding pocket. The peptide 
backbone, together with the side chains of residues 2, 4 
and 6, form the rear of the binding pocket. The top of the 
binding pocket is formed by the glucosamine sugar 
attached to the side chain of residue 4, which projects 
outward over the concave binding pocket. The fatty-
acyl chain attached to the glucosamine lies on the back 
(convex) face of the antibiotic. This positioning of the 
acyl chain sterically prevents teicoplanin from forming 
the types of back-to-back dimers that are observed with 
many other glycopeptide antibiotics, such as 
vancomycin. An additional sugar moiety, an N-acetyl 
glucosamine attached to amino acid 6, contributes 
steric bulk that may also contribute to blocking back-to-
back dimer formation [91]. 
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I.III NANOPARTICLE SYSTEMS FOR INDUSTRIAL 
APPLICATIONS 
In industrial enzymatic application processes, 
immobilization of enzymes can offer several advantages, 
including the ability to be used repeatedly, improvement 
of enzyme stability and broadening the optimum pH 
range of enzyme [92]. 
III.1 NP@ACYLASE 
Semisynthetic cephalosporins are the most widely used 
antibiotics and are primarily synthesized from 7-
aminocephalosporanic acid (7-ACA), which is usually 
obtained by chemical deacylation of the natural 
antibiotic cephalosporin C (CephC). The chemical route 
includes, however, several expensive steps and requires 
treatment of toxic wastes. A two-step enzymatic route 
can also be used that, in two separate reactors, uses 
DAAO and glutaryl-7-amino cephalosporanic acid 
acylase (gl-7ACA) activity (figure 14). Although this route 
solves the environmental safety problems, it is also 
expensive and not entirely satisfactory for industrial 
production. Therefore, enzymatic conversion of CephC 
to 7-ACA is of great interest to cephalosporin antibiotics 
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manufacturers (an annual worldwide market of 400 
million US dollars has been estimated) [93].  
 
Fig. 14 Bioconversion of CephC into 7-ACA [93]. 
Several groups have attempted to implement a “one-
step” conversion of CephC by using DAAO and gl-7ACA 
in a single reactor, but the process still comprises two 
enzymatic conversions and has some drawback. The 
main problem is that DAAO produces hydrogen peroxide 
as a by-product; H2O2 affects DAAO as well as gl-7ACA 
stability. To solve this problem is necessary also the 
addition of catalase in the reaction.  
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The alternative enzymatic approach is a one-step 
process in which CephC is directly converted to 7-ACA 
by a true CephC acylase. This approach is very 
attractive at the industrial level because of the prospects 
of simplifying the process and reducing costs (figure 15). 
 
Fig. 15: Bioconversion of CephC. Left: two-step 
conversion by DAAO and gl-7ACA acylase. 
Right: one step conversion by CephC acylase 
[94]. 
However the great hindrance is that this enzyme takes 
7ACA as primary substrate and its activity is too low for 
CephC.  
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III.1.1 VAC Acylase 
Gl-7ACA acylase are members of the N-terminal 
hydrolases class of hydrolytic enzymes. According to their 
substrate specificity and sequence conservation, known 
glutaryl acylases have been divided into five classes. 
While all gl-7ACA are active on 7-ACA, only member of 
class I and II show an appreciable activity on CephC. Gl-
7ACA acylases form Pseudomonas diminuta N176 
showed the highest activity on both 7-ACA and CephC 
[94]. Numerous effort have been made for improve N176 
acylase activity on CephC. Recently Pollegioni et al. 
designed, on the basis of the primary sequence of N176 
acylase, a synthetic gene named VAC, which has been 
used as the starting scaffold to develop a CephC 
acylase. They introduced genetic variability into the VAC 
cDNA using random mutagenesis and saturation 
mutagenesis, finding 3 mutants showing an increase in 
kinetic efficiency on CephC compared to wild-type VAC 
(see table 2). Among these mutants H296S-H309S has the 
lowest Km and a decrease of 22-fold in the kinetic 
efficiency on 7-ACA compared to wild-type. Moreover, 
like other mutants, H296S-H309S do not shows any 
substrate inhibition and is less sensitive to inhibition by 
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product [93]. For these reasons in this study the mutant 
H296S-H309S was used. 
 
Tab. 2 Kinetic properties of purified wild type and 
mutants of VAC on CephC and 7ACA as 
substrate. Highlighted mutant used in this study 
[93]. 
With the aim to further improve the one-step conversion 
of CephC to 7-ACA H296S-H309S VAC acylase was 
immobilized to Fe3O4 magnetic NPs. This conjugation 
could allow a simplest reuse and a greater stability of the 
enzyme, leading to a reduction of costs. 
III.2 NP@LASPO 
The last enzyme system for industrial application 
designed in this study is composed of Fe3O4@APTES NPs 
conjugated to L-aspartate oxidase (LASPO).  
III.2.1 LASPO 
LASPO is a prokaryotic enzyme that catalyzes the first 
step of de novo nicotinamide adenine dinucleotide 
(NAD+) biosynthesis: the product iminosuccinate in vivo is 
condensed with dihydroxyacetone phosphate resulting 
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in the production of quinolinate and, eventually, NAD+. In 
vitro LASPO can use both O2 and fumarate in cofactor 
re-oxidation, which enables it to perform catalysis under 
both aerobic and anaerobic condition. In fact, under 
aerobic condition, free LASPO oxidizes L-aspartate to 
iminosuccinate, which is then nonenzymatically 
hydrolyzed to oxaloacetate (figure 16). 
 
Fig. 16 oxidation of L-aspartate to 
iminosuccinate by LASPO and subsequent 
nonenzymatically hydrolyzation to oxaloacetate 
[96].  
Among LASPO from different prokaryotes, those from 
thermophilic microorganisms, such as Sulfolobus tokodaii 
(StLASPO), are of potential interest. StLASPO is 
monomeric (52 kDa) in solution, show the classical 
properties of FAD-containing oxidases and possesses a 
high thermal stability: the enzyme is fully stable at 80°C. 
StLASPO shows distinctive features that makes it an 
attractive tool for biotech applications: high thermal 
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stability and high temperature optimum, stable activity in 
a wide range of pH (7.0-10.0), weak inhibition by the 
product oxaloacetate and by D-aspartate and thigh 
binding of the FAD cofactor. Recombinant StLASPO was 
efficiently used for the resolution of a racemic mixture of 
D, L-aspartate: low amount of StLASPO (9U) allowed to 
reach quantitative conversion and >99.5% e.e.. Indeed 
and because of the high stability, this enzyme can be 
used for additional cycles of bioconversion. Conjugation 
on a support like NPs could further improve StLASPO 
qualities [95, 96, 97].  
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II.I: MATERIALS AND METHODS 
IN VITRO STUDIES 
ENZYMES 
In this work three variants of DAAO were used: the wild 
type RgDAAO (named DAAO) and two mutants, 
R285ADAAO (named R285A) and 1903DAAO (named 
1903). In the first mutant the arginine (R) 285 has been 
substituted with an alanine (A), generating a non-active 
DAAO [98]. 1903 mutant contains 5 amino acid 
substitutions: Serine in 19 has been substituted with 
glycine (S19G), serine in 120 with proline (S120P), lysine in 
321 with methionine (K321M), alanine in 345 with valine 
(A345V) and glutamine in 144 with arginine (Q144R). 
These substitutions do not affect the contents of 
secondary and tertiary structure of the protein, but 
enhance the activity of the enzyme at low oxygen 
concentrations [99]. 
Fe3O4 NPs@APTES 
 
Fig. 17 Functionalization of Fe3O4 NPs with APTES. 
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150mg of Fe3O4 NPs (Sigma, n.cat: 637106) were 
ultrasonicated in 10ml of H2O MilliQ for 15min. A solution 
of 5ml APTES (2% v/v, Sigma n.cat. A3648) in H2O MilliQ 
was then added and the reaction was maintained 
under mechanical stirring for 5h at 50°C, according to 
del Campo et al. [24]. Fe3O4 NPs@APTES were then 
separated from unbound APTES by a commercial 
parallelepiped neodymium magnet (Webcraft GmbH, 
Uster, Switzerland; Ni-Cu-Ni plated; magnetization: N45; 
size: 30x30x15 mm), washed several times with water and 
anhydrificated with ethanol overnight. NPs were 
suspended again in water, ultrasonicated for 30’ and 
leaved at room temperature for 1h. Longer suspended 
nanoparticles were isolated and dried at 50°C overnight. 
Fe3O4 NPs@APTES-DAAO: FIRST METHOD 
 
Fig. 18 Conjugation of DAAO on Fe3O4 
NPs@APTES, method one. 
A suspension of 4mg of Fe3O4 NPs@APTES in 2ml 
glutaraldehyde (0.5% v/v, Sigma n.cat. G6257) in water 
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obtained by ultrasonication for 15min (Sonica® 5300MH; 
Soltec, Milano, Italy) was allowed to react for 2h using a 
rotating plate tube stirrer at room temperature. The 
produced adduct was separated from the supernatant 
with a neodymium magnet, washed three times with 
500µl of MilliQ, then with 500µl of 5mM sodium 
pyrophosphate buffer (NaPPi, Sigma, n.cat. P8135) at pH 
8.5. Functionalized Fe3O4 NPs were suspended in 5mM 
NaPPi pH 8.5 and the mixture sonicated for 1min. Finally, 
250µg of pure RgDAAO was added (1ml of final volume 
of 5mM NaPPi pH 8.5 buffer) and the reaction was 
carried out for 4h at 4°C using a rotating plate tube 
stirrer. Subsequently, Fe3O4 NPs@APTES–DAAO were 
collected by a magnet and washed twice with 1ml of 
5mM NaPPi pH 8.5. The supernatant was stored for further 
analysis.  
Fe3O4 NPs@APTES-DAAO: SECOND METHOD 
 
Fig. 19 Conjugation of DAAO on Fe3O4 
NPs@APTES, method two. 
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4mg of Fe3O4 NPs@APTES were suspended by sonication 
for 15min with 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC, Sigma n.cat: 
03450) and N-Hydroxysuccinimide (NHS, Sigma, n.cat: 
130672) in 3:2 ratio in buffer 5mM NaPPi pH 8.5. 250µg of 
DAAO were added and the reaction was carried out for 
4h at 4°C using a rotating plate tube stirrer.  
Subsequently, Fe3O4 NPs@APTES-DAAO were collected 
by a magnet and washed twice with 1ml of 5mM NaPPi 
pH 8.5. The supernatant was stored for further analysis. 
The same procedure has been used to prepare the 
Fe3O4 NPs@APTES system conjugated with the other two 
DAAO variants used in this work (R285A and 1903). 
SPECTRA ANALYSIS 
The amount of protein bound to Fe3O4 NPs@APTES was 
determined as the difference between the starting 
amount of RgDAAO and the protein recovered in the 
supernatant at the end of reaction. Quantification was 
performed using the extinction coefficient at 455nm 
(12.6mM-1cm-1) using an UV-Vis V-560 spectrophotometer 
(JASCO, MD, USA). Characterization of the NP coated 
samples was performed using the solid phase Fourier 
transform infrared spectroscopy: spectra were collected 
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on Nicolet Avatar 360 spectrometer (JASCO). Samples 
were mixed with infrared grade KBr in a proportion of 
2:100 (w/w). 
DYNAMIC LIGHT SCATTERING (DLS) ANALYSIS  
Fe3O4 NPs, Fe3O4 NPs@APTES and Fe3O4 NPs@APTES-
DAAO were analyzed at concentrations of 250µg/ml, 
25µg/ml and 2.5µg/ml in water. Samples dilutions 
(25µg/ml and 2.5µg/ml) were done in order to analyze 
the effect of concentration on NP aggregation. Each 
measurement was preceded by an equilibration time of 
90 seconds. Analyzes were performed with Zetasizer 
Nano ZS90 (Malvern, UK) instrument. Measures were 
reported as scattering intensity in function to diameter.  
Fe3O4 NPS@APTES-DAAO CHARACTERIZATION 
Fe3O4 NPs@APTES-DAAO prepared with the two methods 
were characterized by IR analysis in different conditions. 
Samples (disks of 2 cm2 area, ~10 mg cm-2) were placed 
in a quartz cell equipped with KBr windows. A movable 
quartz sample holder allows to adjust the pellet in the 
infrared beam for spectra recording and to displace it 
into a furnace at the top of the cell for thermal 
treatment. The cell was connected to a vacuum line for 
evacuation (Presidual = ~10-6 Torr) and for the 
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introduction of gases into the infrared cell. Spectra were 
recorded at room temperature. The addition of well 
known doses of gas in the cell was possible via a 
pressure gauge for the control of the gas pressure. A 
Nicolet Nexus spectrometer equipped with a Mercury 
Cadmium Telluride (MCT) cryodetector and an 
extended KBr beam splitter was used for the acquisition 
of spectra in the 600?5500 cm-1 range. IR spectra are 
absorption spectra and the notation used is a.u. for 
absorption units. The resolution of the spectra was 4cm-1, 
and 256 scans were accumulated for each spectrum. 
Three kinds of experiments have been performed: first 
the samples have been dispersed in the KBr, then on the 
surface of a silica pellet; finally on a silicon disk. In details: 
- A wafer containing 98 mg of KBr has been 
pressed at 4 tons/cm2, together with ~2 mg of the 
targeted sample; 
- A wafer of 20 mg silica has been casted mixing in 
its center ~6-7 mg of sample, then pressed to 2 
tons per squared cm; 
- ~2 mg of powder have been dispersed on the 
surface of a silicon disk (2 cm²) by the help of a 
spot of ethanol. 
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DAAO ACTIVITY ASSAY 
The activity of Fe3O4 NPs@APTES–DAAO (and of variant 
systems) was determined by measuring the absorbance 
increase accompanying the H2O2-induced oxidation of 
O-dianisidine. One DAAO unit corresponds to the 
amount of enzyme that converts 1µmol of substrate per 
min at 25°C and at 0.253mM oxygen concentration. The 
standard assay mixture contained 890µl of 100mM D-Ala 
in 100mM NaPPi pH 8.5 buffer, 100µl 3.2mg/ml O-
dianisidine in water, 10µl of 0.4mg/ml horseradish 
peroxidase in 100mM NaPPi pH 8.5 buffer, and 10µl of 
0.4mg/ml Fe3O4NPs@APTES–DAAO in the same buffer. 
The reaction was initiated by the addition of the enzyme 
and the absorbance increase was monitored at 440nm 
for 1min using an UV-Vis V-560 Spectrophotometer. The 
initial velocity at different substrate concentrations (0.1–
100mM) were recorded and used to calculate the 
apparent kinetic parameters using the KaleidaGraph 4.0 
software (Synergy Software, PA, USA). 
HPLC MEASUREMENTS 
D- and L-serine cellular concentrations were determined 
according to Sacchi et al. [100]. In detail, a fixed amount 
(5×105 cells) of SKOV-3 or U87 cells were homogenized in 
II.I - MATERIALS AND METHODS 
 
Chapter II- SYNTHESIS OF MAGNETIC NANOPARTICLE SYSTEMS FOR 
CANCER THERAPY: NP@DAAO  Pag. 51 
 
1ml of cold 5% trichloroacetic acid and then centrifuged 
at 16,000×g for 45min at 4°C. Trichloroacetic acid was 
stripped six times from the supernatant using diethylether 
before lyophilization and storage at -20°C. Lyophilized 
cell samples were dissolved in 90µl of 0.1M sodium borate 
buffer, pH 10.4. For amino acid derivatization, 3µl of U87 
or 15µl of SKOV-3 samples were treated with 24µg of N-
acetyl-cysteine and 7.5µg of o-phthaldialdehyde in 0.1M 
sodium borate buffer, pH 10.4.  
HPLC separations were performed on a Symmetry® 
Column C8 (Waters, Milano, Italy; 5 µm) kept at 30°C 
using a JASCO HPLC system. Flow rate was set at 
1ml/min; L- and D-serine were eluted with an isocratic 
method using 0.1M sodium acetate and 1% 
tetrahydrofuran at pH 6.2. Derivatized amino acids were 
detected using a fluorescence detector: excitation at 
344nm and emission at 443nm. D- and L-serine 
quantification was performed by a calibration curve set 
up using increasing concentrations of standard d-serine 
(0.25–10pmol) and l-serine (10–200pmol). 
CELL CULTURE TEST  
SKOV-3 and HCT116 cell lines were maintained as 
adherent cells in RPMI1640 medium, while U87 cell lines 
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were maintained in DMEM medium, at 37°C in a 
humidified 5% CO2 atmosphere. RPMI1640 medium was 
supplemented with 10% fetal bovine serum, 1% L-
glutamine and 1% penicillin/streptomycin solution, 
whereas DMEM medium was supplemented with 10% 
fetal bovine serum, 1% L-glutamine, 1% 
penicillin/streptomycin and 1% sodium pyruvate. Cells 
were passaged as needed using 0.25% trypsin–EDTA.  
CELL VIABILITY  
Cell viability was determined with three different assays: 
as ATP content by using CellTiter-Glo Luminescent Cell 
Viability Assay, as activity of mitochondrial 
dehydrogenases using Cell proliferation Kit (XTT based) 
and as effective viability measuring membrane integrity 
with Neutral Red Staining.  
For all assays 200µl of cell suspension (containing 2×104, 
1×104, 5×103 or 25×102 cells, depending of the exposure 
time) were seeded into 96-well assay plates and 
cultivated for 24h at 37°C in 5% CO2 to equilibrate and 
become attached prior the treatment. Cells were then 
exposed to increasing amounts of naked Fe3O4 NPs for 
0.5, 1, 2, 24, 48 and 72 h. In another series of experiments, 
1×104 cells were exposed to increasing amounts of free 
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DAAO or Fe3O4 NPs@APTES–DAAO for 24h. Following the 
treatment, plates were treated in different ways 
depending on the kit used, always according to 
manufacturer’s instruction.  
CELLTITER-GLO LUMINESCENT CELL VIABILITY ASSAY 
Plates were equilibrated for 30min at room temperature 
and 100µl of CellTiter-Glo Reagent were then added to 
each well. Plates were shaken for 2min and left at room 
temperature for 10min prior to the recording of 
luminescent signals using the Infinite F200 plate reader 
(Tecan Group, Männedorf, Switzerland). For all cell lines, 
experiments were performed in triplicate. Cell viability, 
expressed as ATP content, was normalized against 
control values. The same procedure has been used for 
free mutant DAAOs and Fe3O4 NPs@APTES–
mutantDAAO. 
CELL PROLIFERATION KIT (XTT BASED) 
50µl of Reaction solution were added to each well and 
plates were incubated for 4h at 37°C. Then plates were 
shaken for 2min and Abs at 450nm (specific signal) and 
630nm (non-specific signal) were measured using the 
Infinite F200 plate reader (Tecan Group, Männedorf, 
Switzerland). Final Abs was obtained by subtraction of 
non-specific to specific signal. For all cell lines, 
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experiments were performed in triplicate. Cell viability 
was normalized against control values.  
NEUTRAL RED STAINING 
Medium with NPs was removed, cells were washed with 
PBS (Sigma), 100µl of Neutral Red Medium (Sigma, 
40µg/ml in cell medium) were added in each well and 
cells were leaved for 2h at 37°C. Neutral Red Medium 
was then removed, wells were washed with 100µl of PBS 
and 150µl of Neutral Red Solution (50% ethanol, 49% H2O, 
1% acetic acid) were added. Plates were shaken for 
10min and Abs at 540nm was measured using the Infinite 
F200 plate reader (Tecan Group, Männedorf, 
Switzerland). Abs is directly proportional to viability. For all 
cell lines, experiments were performed in triplicate. Cell 
viability was normalized against control values. 
MEASUREMENT OF O2 CONCENTRATION IN THE CELL MEDIUM 
The effect of U87 metabolism on the concentration of O2 
in the cell medium was assessed by measuring the 
oxygen consumption with a Hansatech oxygen 
electrode. Experimental conditions are reported in table 
3:  
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96well 
plate 
1 2 3 4 5 6 7 8 9 10 11 12 
A Medium DMEM  
B U87 incubation for 24h 
C 
U87 treated for 24h with 10mU 1903 + D-Ala 20mM 
D 
U87 treated for 24h with 10mU DAAOwt + D-Ala 20mM 
E U87 incubation for 48h in DMEM medium 
F 
U87 incubation for 48h in DMEM medium with medium 
changing every 24h.  
G U87 treated for 24h with 200mU 1903 + D-Ala 20mM 
H 
U87 treated for 24h with 200mU DAAOwt + D-Ala 20mM 
Tab 3 Plate scheme used for O2 depletion 
measures. 
CELLULAR UPTAKE 
Cellular uptake and localization was determined on 
SKOV-3, U87 and HCT116 cells exposed to Fe3O4@APTES–
DAAO for 24h and analyzed by transmission electron 
microscopy (TEM) and optical microscopy (OM). For TEM 
studies, exposed cells were harvested, fixed in 2% 
glutaraldehyde in 0.1M sodium cacodylate buffer (pH 
7.2) for 10min on ice and for 30min at room temperature, 
washed in the same buffer, and postfixed in dark for 1h 
with 1% osmium tetroxide in 0.1M sodium cacodylate 
buffer (pH 7.2) at room temperature. After standard 
steps of serial ethanol dehydration, samples were 
embedded in an Epon-Araldite 812 1:1 mixture (Sigma). 
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Thin sections (70nm) were obtained with a 
ReichertUltracut S ultratome (Leica, Wetzlar, Germany), 
stained by standard methods with uranyl acetate and 
lead citrate, and observed with a JEOL 1010 electron 
microscope (JEOL, Tokyo, Japan) operated at 90kV. 
For OM 5x103 cells were seeded on a coverslip and 
cultivated for 24h at 37°C in 5% CO2 to equilibrate and 
become attached prior the treatment. Cells were then 
exposed to 40µg/ml Fe3O4 NPs naked and 40µg/ml Fe3O4 
NPs@APTES-DAAO for 24h at 37°C in a humidified 5% CO2 
atmosphere. Cells were then washed twice with 1ml of 
PBS complete, fixed with cold ethanol for 5min and 
colored with 1ml of Prussian’s Blue (2% hydrochloric acid 
mixed with 2% potassium ratio 1:1). After two washings 
with H2O, cells were colored with 1ml of 0.5% Neutral Red 
solution for 3min, washed 3 times with H2O and mounted 
on a slide. 
STATISTICS 
Kinetic data and cell viability values were expressed as 
mean ± standard deviation. Statistical tests were 
performed using KaleidaGraph 4.0 software (Synergy 
Software). 
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IN VIVO STUDIES 
Two in vivo studies have been performed. In both 
experiments CD1 (CD1 (ICR), Charles River Labs Italia 
S.p.A. Calco, Lecco) male mice were intravenously 
treated with a single dose of Fe3O4 NPs@APTES-DAAO 
and sacrificed 24h after treatment. All mice were 5 
weeks old on the day of dosing and were able to 
acclimate for 7 days before treatment. In the first 
experiment mice were injected with 100mg/kg of NPs in 
NaCl 0.9%, while in the second with 20mg/kg of NPs in 
NaPPi buffer pH 7.4. 
CLINICAL AND BEHAVIOURAL OBSERVATION  
Animals were weighted before treatment and before the 
sacrifice and clinically monitored after the treatment.  
The behavioral observation (Irwin test) was performed 
only at the beginning of the study when the substance 
was administered for the first time. The test was 
performed according to the method described by Irwin 
[101] at time 5, 15, 30, 60 min after treatment.  
CLINICAL CHEMISTRY AND HEMATOLOGY  
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Before necropsy, blood was drawn by intracardiac 
puncture, collected in heparinized tubes and analyzed 
for:  
• Biochemical parameters: albumin (ALB), total 
protein (PT), creatinine (CRE), urea, triglyceride 
(TG), transaminase (ALT/GPT). 
• Complete blood count, platelet count, white 
blood cell (WBC), red blood cell (RBC), 
hemoglobin (Hb), hematocrit (Ht), mean 
corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC). 
SACRIFICE, SAMPLING, AND PATHOLOGICAL EXAMINATION 
PROCEDURES  
Mice were euthanized at 24h post treatment according 
to standard procedures and in compliance with local 
regulations.  
Complete necropsy of mice was performed. Liver, spleen 
and kidney were weighed and the relative organ weight 
(wet organ/total body weight) was calculated.  
Liver, kidney, spleen, lung, heart, brain were sampled, 
fixed in 10% NBF, and paraffin embedded according to 
standard MAPLab procedures. 4µm sections from each 
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tissue were routinely stained with Hematoxylin-Eosin (HE) 
and evaluated under a light microscope.  
4µm sections from each tissue were routinely 
immunostained with anti-Iba-1 antibody (identification of 
histiocytes) and evaluated under a confocal 
microscope.  
STATISTICAL ANALYSIS  
Statistical significance was assessed by analysis of two-
tailed Student’s t-test to compare the experimental 
conditions with the negative control (p<0,05). 
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II.II: RESULTS AND DISCUSSION 
SAMPLE CHARACTERIZATION 
Fourier transform infrared spectra of Fe3O4 NPs and Fe3O4 
NPs@APTES are shown in figure 20.  
 
Fig. 20 Fourier Transform infrared spectra of 
Fe3O4 NPs and Fe3O4 NPs@APTES. 
The peak within 550–570 cm-1 is characteristic of Fe-O 
vibrations related to the magnetite core. The presence 
of silane on the surface of NPs is confirmed by the 
presence of characteristic peaks; the peak at 1006cm-1 
is indicative of the Si-O bond; the peaks at 3470 and 
1627cm-1 are indicative of the N-H stretching and 
bending vibrations overlapped with those of vibration 
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bands of hydrogen-bonded silanols (SiOH groups). Fe3O4 
NPs@APTES expose the –NH2 groups, allowing NPs to 
remain dispersed in the medium.  
DLS ANALYSIS 
In all samples NPs aggregates of 300nm or more are 
evident. The size of the aggregates varies with the 
dilution: at increased dilution the diameter decreases. 
The polydispersity index (pdl) increases from Fe3O4 NPs to 
Fe3O4 NPs@APTES-DAAO. It seems that the enzyme 
conjugation process induces aggregation. To confirm 
this it can be noted that the population of Fe3O4 
NPs@APTES-DAAO is stable around a dimensions of 1µm 
(figure 21c). 
II.II- RESULTS AND DISCUSSION 
 
Chapter II- SYNTHESIS OF MAGNETIC NANOPARTICLE SYSTEMS FOR 
CANCER THERAPY: NP@DAAO  Pag. 62 
 
 
Fig. 21 DLS analysis on Fe3O4 NPs (a), Fe3O4 
NPs@APTES (b) and Fe3O4 NPs@APTES-DAAO (c) 
at different concentrations. 
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DAAO BINDING EFFICIENCY AND Fe3O4 NPS@APTES-DAAO 
KINETIC PROPERTIES 
RgDAAO was conjugated to Fe3O4 NPs@APTES by two 
different methods described in II.I Materials and Methods 
section and summarized in figure 22.  
 
Fig. 22 Schematic representation of the two 
DAAO conjugation methods on Fe3O4 
NPs@APTES. a) Conjugation via glutaraldehyde 
b) Conjugation via EDC and NHS. 
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Tab 4 comparison of binding efficiency between 
the two methods of DAAO conjugation on Fe3O4 
NPs@APTES. 
The second method is much more efficient as 
highlighted in table 4. In fact, the amount of enzyme 
bound to NPs with the first methods is approximately 
70%, with an enzymatic activity of 4.5U/mg NPs. The 
second method reaches the 100% of binding efficiency 
with an enzymatic activity of 7U/mg NPs. This method is a 
good optimization of the process of conjugation, 
reaching the ultimate goal in terms of quantity and 
activity of enzyme bound. Furthermore this method 
allows a reduction of 2h of the working times. As what 
concern system stability, no differences have been 
highlighted between the two methods: DAAO activity 
remains stable for 2 weeks at 4°C and a 20% decrease 
was observed after 2 months. Both coating procedure 
did not affect the kinetic properties of DAAO, in fact the 
apparent Km of immobilized enzyme for D-Ala was 
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identical to that of the free enzyme (0.9 vs 1 mM), as 
shown in figure 23. Altogether, this conjugation 
procedure does not seem to alter the flavoenzyme 
conformation and its binding with the flavin adenine 
dinucleotide cofactor, which is absolutely required for its 
catalytic activity. 
 
Fig. 23 Michaelis–Menten plot of the activity 
measured for Fe3O4 NPs@APTES-DAAO and free 
DAAO at increasing D-Ala concentrations. 
FE3O4 NPS@APTES-DAAO CHARACTERIZATION 
The spectra of Fe3O4 NPs@APTES-DAAO prepared with 
the two methods, dispersed in the KBr, are reported in 
figure 24. 
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Fig. 24 IR spectra of Fe3O4 NPs@APTES-DAAO 
prepared via glutaraldehyde (red) and via 
EDC/NHS (blue). Samples were dispersed in KBr 
(2% w/w). 
The two spectra are similar. At the highest wavenumbers 
we can observe the stretching of the OH groups of 
water adsorbed on KBr, likely (3425cm-1). In the region 
3300-3000cm-1 the ν(NH) vibration are observed; they 
correspond to the NH2 moieties present in the organic 
ligand. The intensity being relatively low, their 
concentration is minor. The corresponding bending 
mode is at 1650-1640cm-1 and 1546cm-1, partially 
overlapped with the δ(HOH) of water at ~1630cm-1. 
Below 800cm-1, only structural (saturated) bands are 
visible, containing bending, twisting and rocking modes, 
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together with the stretches of M-O bonds. The other 
bands (in the 1600-1000cm-1 region) are due to C-C and 
C-O bonds, while those in the 3000-2800cm-1 interval to 
C-H stretches, difficult to be discriminated at this step. 
Interestingly, no bands at ~1745cm-1, typical of the C=O 
bonds of the aldehydes can be distinguished. 
 
Fig. 25 spectral subtraction of spectra of figure 
24: spectrum of Fe3O4 NPs@APTES-DAAO 
prepared with the first method minus that of NPs 
prepared with the second method.  
Performing a spectral subtraction we can better 
scrutinize the differences in the two compounds: the 
vibrations associated to the NH2 species almost 
disappear in the compound prepared via EDC/NHS, as 
indicated by the bands in positive in the difference 
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spectrum (3400-3000cm-1 region, plus 1649 and 1546 cm-1 
peaks) and by the absence of the corresponding bands 
in the blue spectrum in Fig. 24. A very weak feature 
appears at 1735cm-1, accounting for aldehyde typical 
vibration, confirming that traces of these free vibrations 
can be seen on the glutaraldehyde sample. Therefore 
we can conclude that all the ligands are functionalized 
in the EDC/NHS sample, whereas only a small portion of 
them present free coordination ends in the 
glutaraldehyde compound. By the way, also silanol 
signals (as indicated by the material structural formula) 
are totally absent (band expected at 3746cm-1), 
probably been taken in a hydrogen bonding 
configuration. 
When dispersing the samples on silica (figure 26), the 
observed bands essentially deal with OH groups on silica 
(3746cm-1) and adsorbed water (~3450 and 1630 cm-1). 
The features at 1972 and 1867 cm-1 are overtones and 
combination bands of silica framework (massif below 
1300cm-1) (spectrum blue, Fig. 26). After CO or NO 
adsorptions, no remarkable differences can be 
distinguished especially on the glutaraldehyde sample 
(spectra at the bottom of the figure, cyan, magenta 
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and green). In the case of the EDC/NHS sample, a weak 
component appears at 1508cm-1 (spectrum red, red 
arrow), which cannot be related directly with the probe 
molecules. Eventually, it could be ascribed to CO 
interactions with some accessible ligand in the organic 
part, inducing a shift in a C-C or C-O vibration. 
 
Fig. 26 Spectra of samples dispersed in silica. In 
the bottom part in blue subtraction spectrum of 
glutaraldehyde and EDC/NHS samples, in cyan, 
magenta and green spectra of glutaraldehyde 
samples after NO and CO adsorption. In the 
upper part EDC/NHS samples spectra after CO 
adsorption. Arrow indicates peak at 1508cm-1. 
Subtraction spectra (figure 27) confirm that no effect of 
probe molecule adsorption can be detected, so 
witnessing for an absence of coordinative unsaturated 
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sites on the cationic iron species. Practically, we can 
conclude that all the iron nanoparticles are totally 
surrounded by the organic compounds. 
 
Fig. 27 spectra above: NO adsorption (10 and 18 
Torr at the equibrium) on the glutaraldehyde 
sample; spectrum below: difference before and 
after the adsorption of CO on the EDCNHS 
sample. 
Finally, we tried to characterize the samples after 
deposition on a silicon wafer. The corresponding spectra 
are reported in figure 28. Besides the interference fringes 
due to the specular surfaces of the Si disks, we can 
observe only bands due to the organic ligands, already 
mentioned above. Comparing the spectra during the 
adsorption of CO and after evacuation (B & A for 
glutaraldehyde, respectively, and C & D for EDC/NHS), 
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we cannot observe any difference, if we exclude the 
changes in the baseline, irrelevant for the present study. 
Even, this latter approach for the sample analysis seems 
less appropriate, providing spectra of relatively low 
quality. 
 
Fig. 28 samples spectra collected on a silicon 
wafer. A and B are glutaraldehyde samples 
while C and D EDC/NHS samples. 
In conclusion, we can say that the EDC/NHS sample 
higher activity in respect with glutaraldehyde sample is 
due to a higher efficiency of bound. In fact, apparently 
all available NH2 sites are saturated with DAAO, while 
glutaraldehyde sample shows some free NH2 and 
aldehyde sites. Moreover all conjugation sites of Fe3O4 
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NPs are saturated, indicating that APTES functionalization 
is absolute. 
CYTOTOXICITY 
In this study three tumor cell lines have been used. We 
chose ovarian carcinomas (SKOV-3), colon-rectum 
adenocarcinomas (HCT116) and glioblastoma (U87) cell 
lines, because representing cancers particularly frequent 
and/or lethal. Colon-rectum adenocarcinomas are the 
third most frequent and lethal cancer. Ovarian cancer is 
the tenth for the frequency but is lethal in the 63% of 
cases. Brain tumors are less frequent, compared to the 
other two cancers, but about 61% of cases results in 
death and glioblastoma is the most common malignant 
primary brain tumor among adults [102].  
Preliminary analyses were done on SKOV-3 to asses 
toxicity of Fe3O4 NPs and Fe3O4 NPs@APTES.  
Data are expressed as a percentage reduction of the 
ATP content and indicate a cell suffering rather than 
death. All experiments were conducted in 100µl, then all 
the amount of NPs used must be considered in that 
volume. 
Fe3O4 NPs seem not to have significant cytotoxic effects 
within 4µg and a higher toxicity is caused by acute 
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treatment 30, 60, 120 min (figure 29a). Fe3O4 NPs@APTES 
show a slightly higher toxicity compared to Fe3O4 NPs, 
especially at the higher doses, 16 and 32 µg (figure 29b). 
This is probably due to the presence of –NH2 groups 
belonging to APTES molecule. 
 
Fig. 29 Cytotoxicity assay on SKOV-3 of Fe3O4 
NPs (a) and Fe3O4 NPs@APTES (b).  
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Being that SKOV-3 exposed to 16µg of Fe3O4 NPs for 24h 
show a viability of 70%, we decided to expose cells for 
24h to the system prepared with the first method (see 
MATERIALS AND METHODS, Fe3O4 NPs@APTES-DAAO, FIRST 
METHOD), in a way that the amount of Fe3O4 NPs within 
the system is not more than 16µg. The toxicity of the 
system was tested with and without D-Ala. This amino 
acid was chosen because it represents the reference 
substrate for DAAO [73]. It should be emphasized that D-
Ala itself had no effect on cell viability at the used 
concentrations (figure 30).  
 
Fig. 30 % ATP content depletion in SKOV-3 
exposed for 24h to D-Ala 1, 10 and 20 mM. 
The efficacy of the system was then tested in 
comparison with the toxicity induced by the free 
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enzyme. The range of concentrations goes from 3.5 to 56 
mU, corresponding to maximum 12.5µg of Fe3O4 NPs 
(figure 31). 
 
Fig. 31 Cytotoxicity assay on SKOV-3 of Fe3O4 
NPs@APTES-DAAO and free DAAO with and 
without the substrate D-Ala 1mM. 
In absence of D-Ala, free DAAO did not affect viability. 
When D-Ala was added, a clear effect was seen. As far 
as it concerns Fe3O4 NPs@APTES-DAAO, it exerts a certain 
degree of toxicity also in absence of D-Ala. Noteworthy 
the cytotoxicity is drastically increased by D-Ala 
addiction, depleting completely the ATP content 
already at the lower tested concentration of 3.5mM. The 
conjugation of DAAO to NPs seems to enhance the 
efficacy of the enzyme on tumor cells. In light of these 
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preliminary results, we decided to reduce the range of 
units used (from 3.5 to 14 mU) and we have tested the 
system prepared with the second method (see MATERIALS 
AND METHODS, Fe3O4 NPs@APTES-DAAO, SECOND 
METHOD) on SKOV-3 (figure 32).  
 
Fig. 32 Comparison of cytotoxicity of Fe3O4 
NPs@APTES-DAAO prepared with the two 
methods, with and without D-Ala 1mM, on 
SKOV-3. 24h treatment. 
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No significant differences are evident between the two 
systems. Worthy to note is that the second system allows 
using a lower amount of Fe3O4 NPs, because of the high 
efficiency in the enzyme conjugation. Considered this 
and the reduced production times, the second method 
has been used for the production of all Fe3O4 NPs@APTES-
DAAO for the next experiments. 
In light of all these preliminary results, the system with or 
without D-Ala 1mM was tested on all cell lines (SKOV-3, 
U87 and HCT116), in comparison with the free enzyme in 
the same conditions (figure 33). 
Figure 33 confirms the non-toxicity of the DAAO without 
its substrate and the higher toxicity of the system with D-
Ala in respect to free enzyme in the same conditions. U87 
cells are less sensitive to the treatment and are insensitive 
to the free enzyme with D-Ala. This increases the 
importance of our system in the treatment of brain tumor. 
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Fig. 33 % ATP content depletion in SKOV-3 (a), 
U87 (b) and HCT116 (c) cell lines after 24h 
exposure to Fe3O4 NPs@APTES-DAAO and DAAO 
with and without D-Ala 1mM. 
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The toxicity of Fe3O4 NPs@APTES-DAAO without D-Ala 
may have two reasons. On the one hand there may be 
some non-saturated –NH2 group that enhance the 
toxicity of Fe3O4 NPs. On the other hand there may be D-
amino acid in culture medium or within the cells, which 
may act as endogenous substrate for the enzyme. In 
order to check this last hypothesis, we have measured 
the content of D-serine in SKOV-3 and U87. D-Ser is one of 
the major substrate of DAAO and represents the most 
abundant natural D-amino acid in different brain cells 
[103]. HPLC analysis showed that the cellular D-Ser 
content was approximately 1% of the total (L- and D-) 
serine levels in both cell lines (table 5).  
Cell line 
pmol D-Ser/104 
cell 
pmol L-Ser/104 cell 
D-Ser/(D+L)-Ser 
(%) 
U87 0.86 64.2 1.3 
SKOV-3 0.15 11.2 1.4 
Tab 5 U87 and SKOV-3 content of D- and L-serine 
measured by HPLC analysis. 
Accordingly, if oxidized by DAAO, the natural content of 
D-Ser should result in the same H2O2 production and, 
thus, should similarly affect the viability of cell lines during 
treatment. The presence of D-serine within the cells as 
well as in the culture medium could certainly activate 
DAAO, affecting cell viability in the same way in all cell 
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lines. As a matter of fact cytotoxicity induced by the 
system without D-Ala in all cell lines is the same. 
To confirm that the toxicity was mainly due to the 
enzyme activity, cells were also exposed to the non-
active mutant R285A, in the same conditions previously 
used. Results (figure 34) confirmed that free R285A in 
presence or not of D-Ala does not affect ATP content, 
while Fe3O4 NPs@APTES–R285A accounts, at most, for 40% 
of ATP reduction. Moreover Fe3O4 NPs@APTES–R285A 
toxicity is comparable to that induced by Fe3O4 
NPs@APTES. This once again confirms that the toxicity 
induced by Fe3O4 NPs@APTES-DAAO is caused both by 
the presence of not saturated -NH2 groups and by the 
presence of endogenous substrate. 
Fe3O4 NPs@APTES-DAAO toxicity on the three cell lines 
was furthermore investigated with two toxicity assays: XTT 
and Neutral Red (NR). These two essays give a direct 
estimate of viability and they base respectively on the 
activity of mitochondrial enzymes and on the ability of 
viable cells to incorporate the dye in the lysosomes. 
Results in figures 35 and 36 confirm the higher toxicity of 
the system with its substrate in respect to the free enzyme 
in the same conditions. Moreover both XTT and NR assays 
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indicate that Fe3O4 NPs@APTES-DAAO without D-Ala 
induce cellular suffering rather than death: viability is still 
at 100% even at the higher tested concentration for all 
cell lines. 
 
Fig. 34 ATP content depletion in SKOV-3 (a), U87 
(b) and HCT116 (c) cell lines after 24h exposure 
to Fe3O4 NPs@APTES-R285A and R285A with and 
without D-Ala 1mM. 
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Fig. 35 XTT assay on SKOV-3 (a), U87 (b) and 
HCT116 (c) cell lines after 24h exposure to Fe3O4 
NPs@APTES-DAAO and DAAO with and without 
D-Ala 1mM. 
 
Fig. 36 Neutral Red assay on SKOV-3 (a), U87 (b) 
and HCT116 (c) cell lines after 24h exposure to 
Fe3O4 NPs@APTES-DAAO and DAAO with and 
without D-Ala 1mM. 
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Comparing the three cytotoxicity assays, ATP CellTiter-
Glo luminescent cell viability assay is the better one, 
even though it does not provide a direct measure of cell 
viability. It is very fast and convenient, both in its 
preparation and its use; It is stable (the results can be 
read up to 5h after treatment) and reproducible. This is 
why it was used for all further cytotoxicity assays. 
Looking at all cytotoxicity assays, one can say that U87 
cell line is generally less sensitive to the treatment. One of 
the possible reasons is that the metabolism of these cells 
depletes oxygen concentration in the medium, reducing 
DAAO activity. To check this hypothesis the 1903 mutant, 
more active at low oxygen concentration, was 
conjugated on NPs and tested on U87 (figure 37). 
Moreover the oxygen consumption was measured in 
different experiment condition. The mutant 1903DAAO 
does not seem to be more active on U87 (Fig. 37a), 
indicating standard level of oxygen concentration in 
medium. Further confirmations of this are results deriving 
from oximeter analysis: oxygen concentration in the 
medium even after 48 hours of incubation is almost 
unchanged in respect with the initial concentration. 
These results indicate that the lesser effectiveness of the 
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enzyme on U87 is not attributable to a lowering of 
oxygen. Other mechanisms are then responsible for the 
decrease in DAAO efficiency on U87. However, these 
mechanisms must be sought in the extracellular 
environment characteristics, which change depending 
on the cell type. 
 
Fig. 37 ATP content depletion in U87 cell line 
after 24h exposure to Fe3O4 NPs@APTES-1903 
and 1903 with and without D-Ala 1mM (a). 
Oxygen concentration (nmol/ml) measured with 
a Hansatech oxygen electrode (b). 
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UPTAKE 
Internalization of Fe3O4 NPs@APTES-DAAO was analyzed 
by TEM and OM.  
 
Fig. 38 TEM pictures of SKOV-3 (a, b), HCT116 (c, 
d) and U87 (e) cells exposed to Fe3O4 
NPs@APTES-DAAO for 24h. 
Figure 38 shows that Fe3O4 NPs@APTES-DAAO are 
internalized via endocytosis, in fact pseudopodes (the 
characteristic structure of this pathway) are evident. 
Once entered the cells, the majority of NPs remain in the 
cytoplasm (Fig. 39) inside the endocytic vesicles (Fig. 38c, 
e). Nevertheless vesicles may undergo mechanical 
damage, freeing NPs, which could reach different cell 
districts such as mitochondria (Fig. 38b). However NPs 
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does not enter nucleus, as it is evident by OM images 
(Fig. 39). Moreover NPs does not seem to affect mitosis 
machinery, since nuclei in mitosis are evident (Fig. 39). 
 
Fig. 39 Optical microscope pictures of SKOV-3, 
HCT116 and U87 cells exposed to Fe3O4 NPs and 
Fe3O4 NPs@APTES-DAAO for 24h. 
IN VIVO ANALYSIS  
Mice treated with Fe3O4 NPs@APTES-DAAO for 24 showed 
no relevant behavioral alterations (tab. 6). Also serum 
biochemistry and hematology analysis did not show 
alterations.
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Body weight of mice and relative organ weight of liver, 
spleen and kidneys, expressed as percentages of weight 
gain, of both experiments, are reported respectively in 
tables 7 and 8. 
 
Tab 7 Percentage of body weight gain in mice 
treated with 100mg/kg (on the left, Exp 1) and 
20mg/kg (on the right, Exp 2). 
 
Tab 8 Percentage of relative organ weights gain 
in mice treated with 100mg/kg (on the left, Exp 
1) and 20mg/kg (on the right, Exp 2). 
No significant differences in body weight gain and 
relative organ weight were observed between control 
and Fe3O4 NPs@APTES-DAAO treated groups. The kidney 
relative organ weight of the first experiment was 
significantly lower in treated group than in control group 
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(p<0.05), but this was attributable to the exceptionally 
high relative weight of kidneys in control mice (as 
compared to control mice of other experiments 
performed in similar conditions) and not to a reduced 
relative weight of kidneys in treated group. This finding 
can thus be considered not relevant. 
As regards pathological examination of the first 
experiment, a gross examination shows in the liver of 3/3 
treated mice a diffuse mild black-brown discoloration 
compared to control mice. Histopathological 
examination reported in 3/3 treated mice abundant 
intracytoplasmic iron pigment in the liver, spleen and 
lung and only occasionally in the kidney, lymph nodes 
and intravascular leukocytes. According to histological 
and immunofluorescence analysis, in the liver the Iron 
pigment was found mainly in the cytoplasm of Kupffer 
cells (immunostained with Iba-1), but occasionally also 
within spindle-shaped cells, likely consistent with hepatic 
sinusoidal endothelial cells (figure 40).  
In 3/3 treated mice the following relevant 
histopathological lesions were found: 
Lung: interstitial neutrophilic and histiocytic pneumonia, 
multifocal, mild, chronic with intralesional variably sized 
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aggregates of iron pigment. Occasionally these 
aggregates were large, approx. 50-100 µm in diameter 
(figure 41). 
Spleen: white pulp, follicular reactive hyperplasia mild to 
moderate; red pulp, extramedullary hematopoiesis with 
predominance of myelopoietic precursors and 
megakaryocytes and likely a decrease of erythroid 
precursors. 
In the light of all these findings we can say that the 
slight brown-black discoloration of the liver observed 
grossly in all treated mice was related to the presence 
of abundant iron pigment found in the cytoplasm of 
Kupffer cells.  
Histologically, intracytoplasmic brown granular 
material consistent with visible aggregates of iron-
containing nanoparticles was observed mainly in the 
phagocytic cells of liver, spleen, and lung. These cells 
take Fe3O4 NPs@APTES-DAAO directly from the blood 
stream and store them in their cytoplasm.  
In the lung of all treated mice, the aggregates were 
occasionally very large (up to 100µm), mostly 
associated with interstitial inflammation or occluding 
alveolar septa capillaries (Fig. 41). The presence of 
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large aggregates of iron pigment in the lung may be 
secondary to IV administration of aggregated 
nanoparticles, as suggested by the results of DLS 
analysis (see DLS ANALYSIS), with subsequent 
embolization to the lung.  
In the spleen, reactive follicular hyperplasia was 
observed. This finding may be interpreted as an 
antigenic response, likely directed against the 
enzymatic portion of the nanoparticle 
In general no overt adverse effects have been 
observed at 24 hours after IV administration of 
100mg/kg Fe3O4 NPs@APTES-DAAO, however the 
presence of aggregates of iron-containing 
nanoparticles in the capillaries of the lung, 
occasionally associated with focal histiocytic and 
neutrophilic inflammation should be caused by the 
high dose of NPs injected. 
Pathological gross examination of mice treated with 
20mg/kg, in fact, shows no relevant changes in respect 
with control mice. Histological examination shows in 3/3 
treated mice small to moderate amount of 
intracytoplasmic iron pigment in the liver and spleen. In 
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1/3 treated mice, rare small aggregates were found in 
the lung interstitium (figure 42).  
 
Fig. 40 a) histological examination of mouse 
liver. Arrows indicate iron NPs aggregates. b) NPs 
(green) in cytoplasm of Kupffer cells (red, 
arrows) and in spindled cells (*). Nuclei stained in 
DAPI (cyan). 
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Fig. 41 Histological examination of mouse lung. 
a) Multiple foci of alveolar septa infiltration 
(arrows). b) Alveolar septa infiltrated by 
macrophages and neutrophils surrounding a NPs 
aggregate. c) Dense and homogenous 
aggregate of NPs likely occluding an alveolar 
septum capillary. 
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Fig. 42 histological images of liver (a), spleen (b) 
and lung (c). Brown granular materials, 
consistent with aggregates of NPs, are evident 
(yellow circles and arrows). 
No adverse effects have been observed at 24h after IV 
administration of 20mg/kg Fe3O4 NPs@APTES-DAAO. 
In none of the experiments NPs were found in heart and 
brain. Testis was examined only for animals treated with 
20mg/ml but no positivity was found. This suggests that 
without an external magnetic field, NPs cannot pass 
blood-barriers. 
A summary of Fe3O4 NPs@APTES-DAAO biodistribution is 
reported in table 9. 
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Tab 9 Semi-quantitative results of first and 
second experiment (Exp 1 and Exp 2) of Fe3O4 
NPs@APTES-DAAO accumulation in liver, spleen, 
lung, kidneys, heart and brain. 
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II.III: CONCLUSIONS 
We have designed and produced a NPs-enzyme system 
for cancer therapy: Fe3O4 NPs@APTES-DAAO. Under our 
best experimental condition, we have immobilized 100% 
of the enzyme in term of activity and quantity. The system 
showed an activity of 7U/mg of NPs and an apparent Km 
for D-Ala similar to that of the free enzyme. These results 
are difficult to compare with data in literature [104, 105, 
106] due to the disparate experimental conditions used. 
However, Hsieh et al. reported an immobilization 
efficiency of 85% and a lower conjugated activity than 
our system [106]. Divakaran et al. reported a Fe2O3 NPs 
system conjugate to DAAO from pig (pkDAAO). 
However, maghemite has lower magnetic properties 
than magnetite and pkDAAO has a lower activity than 
RgDAAO, resulting altogether in a system less efficient 
than Fe3O4 NPs@APTES-DAAO [104]. 
In vitro cytotoxicity demonstrates the higher efficacy of 
the system in respect to free enzyme. This is probably due 
to the fact that NPs have the tendency to sediment, 
bringing and accumulating the enzyme near the cells. In 
this way there is a localized production of ROS with an 
enhanced toxicity. Moreover, as seen with optical and 
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transmission microscope, Fe3O4 NPs@APTES-DAAO enter 
the cells producing an oxidative damage inside the cells. 
Also free DAAO can enter cells, but the enzyme tends to 
remain in suspension, the final effect is then a lower 
concentration of DAAO in the environment near the 
cells, and then inside them. 
In vivo experiments did not have highlighted adverse 
side effects of Fe3O4 NPs@APTES-DAAO at a 
concentration of 20mg/kg. At the tested concentrations 
our NPs do not pass brain-blood barrier and do not 
accumulate in the heart.  
Future aim will be to analyze the biodistribution of NPs 
under application of an external magnetic field. Mice will 
be injected with the system and subjected to a localized 
magnetic field. The ability of NPs to accumulate in the 
area affected by the magnetic field will be investigated. 
Moreover, the ability of NPs to cross blood-barriers under 
the magnetic field will be analyzed. Finally system's ability 
to destroy tumor cells in vivo will be tested. 
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III.I: MATERIALS AND METHODS 
Fe3O4 NPs@APTES 
SEE CHAPTER II, II.I: MATERIAL AND METHODS, Fe3O4 NPS@APTES. 
Fe3O4 NPs@CMCS  
The covalent immobilization of CMCS on Fe3O4 NPs was 
conducted following Liang and Zhang’s method [107] 
with some modifications.  
75mg of Fe3O4 NPs were sonicated for 30min with 4ml of 
200mM sodium phosphate buffer (pH 5) containing 25mg 
of EDC•HCl (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide, Sigma n.cat: 03450) 
and 20mg of N-Hydroxysuccinimide (NHS, Sigma, n.cat: 
130672). 
Activated Fe3O4 NPs were separated from supernatant 
by magnetic decantation and suspended in 3mL of 
200mM sodium phosphate buffer (pH 7) by sonication for 
10min. 1mL of CMCS solution (25mg/mL in 200mM sodium 
phosphate buffer, pH 7) was added and the reaction 
was sonicated for 3h. Finally, Fe3O4 NPs@CMCS were 
washed with water, and dried overnight at 50°C. 
Fe3O4 NPs@APTES-Teicoplanin (electrostatic) 
4mg of Fe3O4 NPs@APTES were suspended in H2O by 
sonication for 15min. 1mg of teicoplanin was added in a 
III.I - MATERIALS AND METHODS 
 
Chapter III- SYNTHESIS OF MAGNETIC NANOPARTICLE SYSTEM FOR 
ANTIBACTERIAL THERAPY: NP@TEICOPLANIN Pag. 101 
final volume of 1ml or 2ml. The reaction was carried out 
for a period of time between 2 and 3.5 h, in relation to 
the reaction considered, at room temperature using a 
rotating plate tube stirrer.  
Subsequently, Fe3O4 NPs@APTES-Teicoplanin were 
collected by a magnet and washed twice with 500µl of 
H2O. The supernatant was stored for further analysis. 
Fe3O4 NPs@APTES-Teicoplanin (covalent) 
4mg of Fe3O4 NPs@APTES were suspended in H2O by 
sonication for 15min and then 3mg of EDC and 2mg of 
NHS were added. 1mg of teicoplanin was added to a 
final volume of 1ml. The reaction was carried out for 3.5h 
at room temperature using a rotating plate tube stirrer.  
Subsequently, Fe3O4 NPs@APTES-Teicoplanin were 
collected by a magnet and washed twice with 500µl of 
H2O. The supernatant was stored for further analysis. 
Fe3O4 NPs@Teicoplanin 
4mg of Fe3O4 NPs were suspended in H2O by sonication 
for 15min. 1mg of teicoplanin was added in a final 
volume of 1ml. The reaction was carried out for 2h, at 
room temperature using a rotating plate tube stirrer.  
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Subsequently, Fe3O4 NPs@Teicoplanin were collected by 
a magnet and washed twice with 500ml of H2O. The 
supernatant was stored for further analysis. 
Fe3O4 NPs@CMCS-Teicoplanin (electrostatic) 
4mg of Fe3O4 NPs@CMCS were suspended in H2O or PBS 
(depending on the reaction considered) by sonication 
for 15min. 500µg of teicoplanin were added to a final 
volume of 1ml. The reaction was carried out for 5h, at 
room temperature using a rotating plate tube stirrer.  
Subsequently, Fe3O4 NPs@CMCS-Teicoplanin were 
collected by a magnet and washed twice with 500ml of 
H2O or PBS. The supernatant was stored for further 
analysis. 
Fe3O4 NPs@CMCS-Teicoplanin (covalent) 
4mg of Fe3O4 NPs@APTES were suspended in H2O or PBS 
by sonication for 15min with 3mg of EDC and 2mg of 
NHS. 500µg of teicoplanin were added to a final volume 
of 1ml. The reaction was carried out for 5h, at room 
temperature using a rotating plate tube stirrer.  
Subsequently, Fe3O4 NPs@CMCS-Teicoplanin were 
collected by a magnet and washed twice with 500ml of 
H2O or PBS. The supernatant was stored for further 
analysis. 
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QUANTIFICATION OF CONJUGATED TEICOPLANIN 
The amount of antibiotic bound to NPs was determined 
as the difference between the starting amount of 
teicoplanin and the antibiotic recovered in the 
supernatant at the end of reaction. Quantification was 
performed using a calibration line. Fixed wavelength 
measurements were taken using emission wavelength of 
330nm and excitation wavelength of 280nm by a 
JascoFP-750 spectrofluorometer, equipped with a 
software-driven Peltier system.  
DETERMINATION OF THE BIOLOGICAL ACTIVITY: 
MICROBIOLOGICAL ASSAY 
Microbiological assays using Sarcina lutea ATCC9341 
were done, using the medium V0.1 (MV0.1) whose 
composition is: 2.4g/L soluble starch (Difco), 0.1g/L 
dextrose (A.D.E.A), 0.3g/L malt extract (Constantine), 0.5 
g/L yeast extract (Constantine); 0.5g/L triptose (Difco), 
15g/L Agar (Sigma), 1L of deionized water, pH 7.2. 
For the overlay of the microbiological assay, 100µl of S. 
lutea glycerinate were pre-inoculated in 10ml of medium 
AM1 (30.5g/L Antibiotic Medium A, Difco) at 37°C at 
200rpm over-night. 2ml of this pre-culture were 
inoculated in 50ml of LB and incubated at 200rpm at 
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37°C until reaching an OD600 of around 0.4-0.6. 10% (v/v) 
of the S. lutea culture was added to the SNA (Soft 
Nutrient Agar) medium (5g/L peptone, Costantino, 3g/L 
beef extract, Costantino, 5g/L agar, Sigma) and 10ml of 
this solution are used for the overlay on the plates with 
teicoplanin. 
For the microbiological assay, plates with MV0.1 were 
prepared and a drop of Fe3O4 NPs@CMCS-Teicoplanin 
was plated in the center and allowed to dry. The plates 
were placed at 37°C over-night and the zone of 
inhibition was measured for the assessment of 
microbiological activity. Control experiment plating a 
drop of free teicoplanin, Fe3O4 NPs, Fe3O4 NPs@CMCS 
and Fe3O4 NPs@APTES were done. 
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III.II: RESULTS AND DISCUSSION 
TEICOPLANIN CONJUGATION AND QUANTIFICATION 
Several attempts were done for teicoplanin 
immobilization. Three different nanoparticle supports 
were used: Fe3O4 NPs@APTES, Fe3O4 NPs and Fe3O4 
NPs@CMCS. Moreover a number of different reaction 
conditions were tried. Table 10 summarizes reactions 
carried out. 
 
Tab 10 Summary of reaction conditions of 
Teicoplanin immobilization on NPs with 
spectrofluorometer quantification of antibiotic 
bound. 
Despite Fe3O4 NPs@APTES conjugate with covalent 
bound over 80% of the enzyme, no activity was 
recovered with microbiological assay. Also electrostatic 
reaction on Fe3O4 NPs@APTES and Fe3O4 NPs was quite 
satisfactory in term of quantity of bound enzyme (mean 
of 67%), but NPs does not have activity. As what concern 
electrostatic reaction on Fe3O4 NPs@CMCS, a very low 
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quantity of antibiotic conjugates on NPs: 50% in H2O and 
15% in PBS. Moreover microbiological analysis does not 
show any activity. With covalent reaction over 80% of 
antibiotic is able to conjugate on Fe3O4 NPs@CMCS both 
in H2O and PBS. However only antibiotic conjugated in 
PBS has activity (table 11). 
 
Tab 11 Summary of reactions with MIC results 
Being that the only positive activity result was seen with 
Fe3O4 NPs@CMCS-Teicoplanin prepared in PBS with 
covalent bound, the reaction was repeated several 
times. Unfortunately the reaction is not reproducible. In 
fact, though unchanged reaction conditions, Fe3O4 
NPs@CMCS-Teicoplanin do not always show activity. This 
probably because the conjugation reaction is difficult to 
manage and, sometimes, conjugation with the NPs may 
occur in or near the active site of the antibiotic, 
compromising activity. Moreover, even if Fe3O4 
NPs@CMCS-Teicoplanin possess activity at the end of 
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reaction, this is lost during storage at 4°C. Several 
attempt of storage in different condition (H2O or PBS, -
20°C or 4°C) have been made but no correlation can be 
seen. 
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III.III: CONCLUSIONS 
Teicoplanin has been conjugated on Fe3O4 NPs@CMCS 
with efficiency in term of quantity over the 90%. 
Unfortunately, the reaction was not reproducible and 
some problems are associated with storage. The main 
problem is probably due to the wide active site of 
teicoplanin: interactions with NPs may affect some of the 
residues involved in substrate recognition, leading to a 
loss of activity. To overcome this problem, future goals 
relate to the optimization of reaction conditions, trying to 
protect the active site function. 
 
 Chapter IV-  Pag. 109 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
SYNTHESIS OF Fe3O4 NPs@APTES-ACYLASE 
 
IV.I - MATERIALS AND METHODS 
 
Chapter IV- SYNTHESIS OF NP@ACYLASE  Pag. 110 
 
IV.I: MATERIALS AND METHODS 
Fe3O4 NPs@APTES 
SEE CHAPTER II, SECTION II.I: MATERIAL AND METHODS, Fe3O4 
NPS@APTES. 
Fe3O4 NPs@APTES-VAC 
24mg of Fe3O4 NPs@APTES were suspended by 
sonication for 15min with 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC, Sigma n.cat: 
03450) and N-Hydroxysuccinimide (NHS, Sigma, n.cat: 
130672) in 3:2 ratio in buffer 20mM KH2PO4 pH 8. 560µg of 
VAC were added and the reaction (in a final volume of 
2ml) was carried out for 24h at 4°C using a rotating plate 
tube stirrer.  
Subsequently, Fe3O4 NPs@APTES-VAC were collected by 
a magnet and washed twice with 1ml of 20mM KH2PO4 
pH 8. The supernatant was stored for further analysis. 
Fe3O4 NPs@APTES-VAC ACTIVITY ASSAY 
VAC catalyzes the hydrolysis of CephC to 7-ACA. The 
primary amino group of 7-ACA reacts with pDMAB, 
giving a yellow Schiff’s base with a maximum of 
absorbance at 415nm [108]. In detail: 5µl of enzyme (in a 
phosphate buffer at pH 8.0) were incubated with 100µl 
of 2% (w/v) CephC (pH 8.0) for 10 min at 25°C. The 
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reaction was stopped with 600µl of 20% acetic acid, and 
then 133µl of 0.5% (w/v) pDMAB (dissolved in methanol) 
were added and the reaction was incubated for 10min 
at 25°C, before measuring the absorbance at 415nm. 
Fe3O4 NPs@APTES-VAC BIOCONVERSION 
The time course of bioconversion was determined by a 
pH-stat assay. The reaction mixture contained 50mM 
CephC (pH 8.0) and 0.48U of Fe3O4 NPs@APTES-VAC in a 
final volume of 20ml of H2O or 0.48U of free VAC in a final 
volume of 10ml of H2O. Reaction was incubated at 25°C, 
and aliquots were drawn at different times (up to 70h). 
Fe3O4 NPs@APTES with 50mM CephC and Fe3O4 
NPs@APTES with water were used as control. 
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IV.II: RESULTS AND DISCUSSION 
VAC CONJUGATION ON Fe3O4 NPS@APTES 
Several attempts were made in order to find better 
condition for VAC conjugation. Figure 43 summarizes 
reaction performed in different conditions. 
 
Fig. 43 Summary of VAC conjugation reactions 
on Fe3O4 NPs@APTES with % of immobilized units. 
Where not specified, the duration of the 
reaction is 24h and the final volume (fV) is 1ml. 
For all experiments 300µg of enzyme were used 
corresponding to 0.27U. 
In best experimental conditions 90% of units are 
conjugated on Fe3O4 NPs@APTES, the reaction is 
reproducible and activity is stable for several weeks. 
Moreover Fe3O4 NPs@APTES-VAC can be used several 
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times (4/5 times) before a loss in catalytic efficiency may 
occur. It must be noted that free VAC possesses a 
specific activity of 0.9U/mg, this means that Fe3O4 
NPs@APTES-VAC have maximum activity of 0.24U. In light 
of all these results we decided to increase the activity of 
the system by scale-up. Characteristics of the new system 
are summarized in table 12. 
 
Tab 12 Characteristics of Fe3O4 NPs@APTES-VAC 
and its scale up. 
Fe3O4 NPS@APTES-VAC BIOCONVERSION OF CephC 
The ability of the system to convert CephC to 7-ACA was 
investigated using a stirred reactor in comparison to the 
enzymes in the free form.  
Theoretical calculations for the bioconversion with the 
free enzyme indicate that the reaction should be 
completed in 17.4h, while the Fe3O4 NPs@APTES-VAC 
should convert all the substrate in 34.7h (see figure 44). 
The bioconversion time course was followed by the pH-
stat assay and results are shown in figure 44. 
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Fig. 44 CephC bioconversion at 5h (a) 24h (b) 
and 70h (c). Fe3O4 NPs@APTES (in water and 
50mM CephC) and CephC alone were used as 
control. 0.1M NaOH was used to compensate 
pH variation.  
The free enzyme completed the reaction within 22h, 
confirming theoretical calculations. Unfortunately Fe3O4 
NPs@APTES-VAC, do not seems to have a specific 
bioconversion activity. In fact, Fe3O4 NPs@APTES-VAC 
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and Fe3O4 NPs@APTES curves overlap and Fe3O4 
NPs@APTES-VAC reaction continues after 70h (figure 44). 
This indicates that the pH lowering is nonspecific and 
caused by NPs. 
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IV.III: CONCLUSIONS 
Despite the efficiency of VAC conjugation on NPs (90%), 
the low specific activity of the enzyme does not allow to 
obtain en efficient system on an adequate support 
(24mg of NPs for 0.48U if VAC). Moreover bioconversion 
analysis indicates that Fe3O4 NPs@APTES interfere with 
the assay. For this reason there is the need to find other 
methods to assess the bioconversion ability of the 
enzyme (for example by HPLC).  
Moreover in order to make the system more efficient, 
efforts will be done in order to find a VAC mutant with a 
higher specific activity. Future goals relate precisely this 
last point, so as to increase the specific activity of the 
system.
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V.I: MATERIALS AND METHODS 
Fe3O4 NPs@APTES 
SEE CHAPTER II, SECTION II.I: MATERIAL AND METHODS, Fe3O4 
NPS@APTES. 
Fe3O4 NPs@APTES-LASPO 
8mg of Fe3O4 NP@APTES were sonicated for 15min in 
5mM NaPPi pH 8.0. 12mg of EDC (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide, Sigma n.cat: 
03450) and 8mg of NHS (N-Hydroxysuccinimide, 
Sigma, n.cat: 130672) were added under sonication. 
About 0.06U of StLASPO were added and the reaction 
was carried out for 2h at room temperature on a rotating 
plate tube stirrer. The final volume of the reaction was 
2ml. Subsequently, Fe3O4 NPs@APTES–LASPO were 
collected by a magnet and washed twice with 1ml of 
5mM NaPPi pH 8.0. The supernatant was stored for further 
analysis. 
ACTIVITY ASSAY 
The LASPO activity was assayed by measuring the initial 
rate of production of hydrogen peroxide with a coupled 
peroxidase/dye assay. The dye produced by the 
horseradish peroxidase from H2O2 and 4-aminoantipyrine 
was detected spectrophotometrically at 505nm 
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(ε=6.58mM-1cm-1) and 25°C. One unit is defined as the 
amount of enzyme that catalyses the degradation of 
1µmol L-aspartate per minute. Unless otherwise stated, 
the standard assay mixture contained 10mM L-aspartate 
in 50mM NaPPi pH 8.0, 1.5mM 4-aminoantipyrine, 10mM 
phenol, 20µM FAD, 2.5U horseradish peroxidase in a total 
volume of 1ml. 5µl of free LASPO, 40µl of Fe3O4 
NPs@APTES-LASPO and 80µl of reaction supernatant were 
assayed. 
EFFECT OF SUBSTRATE CONCENTRATION ON CATALYTIC 
ACTIVITY OF FE3O4 NPS@APTES-LASPO 
The resolution of D,L-Aspartate was carried out at pH 10. 
Fe3O4 NPs@APTES-LASPO were stored in phosphate buffer 
50mM pH 7.5 at 4°C. After each enzymatic reaction the 
NPs were washed twice with deionized water and reused 
with the opportune reaction solution. 
1U (216mg) of Fe3O4 NPs@APTES-LASPO were suspended 
in a solution of in 0.5ml D,L-Aspartic (50mM, 150mM and 
250mM) pH 10, 200µl of H2O and 2µL of catalase. The 
reaction was conducted at 70°C at 600rpm for 2.30h. 
Every 30min, 40µl were taken from the supernatant, 
derivatized with the OPA-NAC reagent and analyzed by 
high-performance liquid chromatography (HPLC, Zorbax 
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SB-Aq Analitic Column; eluent 100mM sodium acetate 
pH 5,2; flux 0.6mL/min).  
EFFECT OF THE pH ON THE RESOLUTION OF D,L-ASPARTIC 
ACID 150mM  
The resolution of 150mM D,L-Aspartic (final concentration 
of 100mM) at different pH values was carried out. 1U 
(216mg) of Fe3O4 NPs@APTES-LASPO were suspended in a 
solution of 0.5ml 150mM D,L-Aspartic at different pH (8, 9, 
10), 200µl of H2O and 2µL of catalase. The reaction was 
conducted at 70°C at 600rpm for 2.30h. Every 30min, 40µl 
were taken from the supernatant, derivatized with the 
OPA-NAC reagent and analyzed by high-performance 
liquid chromatography (HPLC, Zorbax SB-Aq Analitic 
Column; eluent 100mM sodium acetate pH 5,2; flux 
0.6mL/min). 
 
V.II – RESULTS AND DISCUSSION 
 
Chapter V- SYNTHESIS OF NP@LASPO  pag. 121 
 
V.II: RESULTS AND DISCUSSION 
LASPO CONJUGATION ON Fe3O4 NPS@APTES 
Several reactions were performed to find the best 
conditions for LASPO conjugation. Figure 45 summarizes 
the reactions executed, highlighting the percentage 
efficiency of immobilization in terms of units. 
 
Fig. 45 Summary of LASPO conjugation reactions 
on Fe3O4 NPs@APTES with % of immobilized units. 
The final volume is 1ml for all reactions except for 
the last, for which is 2ml. Dark blue indicates the 
best experimental condition, used for Fe3O4 
NPs@APTES-LASPO preparation for kinetics 
experiments. 
In best experimental condition about 60% of LASPO is 
conjugated on NPs. This means that on 8mg of Fe3O4 
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NPs@APTES about 0.4U of LASPO are conjugated. A 
scale-up was tried, but unfortunately the operation was 
difficult. To avoid excessive waste of the enzyme, it was 
decided to get the required amount (1U immobilized) for 
subsequent experiments performing multiple reactions 
simultaneously, bringing them all together. For this 
purpose 27 conjugation reactions were performed, 
immobilizing about 1U on approximately 216mg of NPs. 
CATALYTIC ACTIVITY 
The ability of the system in the deracemization of D,L-
aspartate mixture was investigated with different 
substrate concentrations. The conversion of the L-
enantiomer was quantified by HPLC. Results are reported 
in table 13 as percentage of enantiomeric excess (ee). 
 
Tab 13 Conversion of D, L-aspartate in function 
of time 
With 50mM D,L-aspartate as substrate the reaction 
reaches the 100% of conversion within 30 minutes, while 
with 150mM and 250mM within 150 and 240 minutes 
respectively. Deracemization time is directly proportional 
to the concentration with an R2 of 0.9934. Then the 
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activity of the conjugated enzyme was tested at three 
different pH values (figure 46). The system seems to be 
more active at pH 9 whereas the free enzyme prefers pH 
10 [96]. No differences can be noted between pH 8 and 
9. 
 
Fig. 46 Conversion of 150mM D, L-aspartic acid 
at pH 8, 9 and 10. 
For all these experiment Fe3O4 NPs@APTES-LASPO were 
reutilized several times, collecting them with the magnet 
and then bringing them back into suspension by shaking. 
Despite this, the NPs do not seem to have lost activity, 
indicating that they are very stable.  
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V.III: CONCLUSIONS 
In this work a StLASPO was conjugated on Fe3O4 
magnetic NPs with an efficiency in term of unit of 60%. 1U 
of enzyme was conjugated on 216mg of NPs. The system 
was efficiently used for the resolution of a racemic 
mixture of D,L-aspartate: 1U converts 250mM of D,L-
aspartate in 240min. Moreover Fe3O4 NPs@APTES-LASPO 
seems to have a stable activity in a wide pH range (8-10), 
with an optimum around pH 9. Indeed and because of 
the high stability of the system, Fe3O4 NPs@APTES-LASPO 
can be used for additional cycles of bioconversion. 
StLASPO with its extraordinary properties, represents an 
appropriate biocatalyst for the resolution of racemic 
resolution of D,L-aspartate and its conjugation on 
magnetic NPs increases its industrial value.  
Future goals will be to repeat the experiments in order to 
confirm the results. Moreover the kinetic properties of the 
immobilized enzyme will be characterized, investigating 
the range of temperature and pH with higher 
performances in terms of activity and stability. Finally, the 
characteristics of immobilized LASPO with those of the 
free enzyme will be compared. 
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In the search for noninvasive diagnostic techniques and new therapies, “nanosystems”, which are capable of binding and targeting
bioactive molecules, are becoming increasingly important. In this context, biocompatible coatings are gaining interest, not only for
their biological efects but also because they are considered capable tomasknanoparticle toxicity. In thiswork,we have compared the
toxicity of nanoparticles coated with heparin and carboxymethylchitosan in the SKOV-3 cell line. Our results indicate that heparin
and carboxymethylchitosan coatings do not guarantee the decrease of nanoparticle intrinsic toxicity which is oten envisaged.
Nonetheless, these coatings provide the opportunity for further functionalization with a variety of biomolecules for their use in
theranostics.
1. Introduction
Nanomedicine, the application of nanotechnology in health-
care, ofers numerous and promising possibilities to signii-
cantly improve medical diagnosis and therapy. New sensitive
diagnostic devices, in fact, will permit very early personal
risk assessment, and the abatement of costs for the disease
treatment is a must for healthcare. Due to its high potential,
nanomedicine holds the promise to greatly improve the
eicacy of pharmaceutical therapy, reduce side efects, and
make drug administration more convenient [1].
In this context, nanoparticles (NPs), particularly mag-
netic nanoparticles (MNPs), coated with biodegradable poly-
mers, are attracting widespread attention for targeted therapy
and imaging.hese coatings can stabilize the NP systems also
in hydrophilic luids, minimize opsonization by themononu-
clear phagocytic system, and prolong blood circulation [2–7].
Furthermore, this surface layer can be functionalized with a
variety of biological moieties for tumor-speciic targeting [8–
10].
Among the biological molecules used for NP coating,
chitosan, particularly carboxymethylchitosan (CMCS), and
heparin appear very interesting also because they are consid-
ered capable to mask NP toxicity [11, 12]. We should not, in
fact, oversee the toxicity of cobalt and nickel oxide NPs [13–
16] nor their potential efect on the environment [17]. Even
though heparin is predominantly used as anticoagulant, its
ability to interact with proteins makes it very attractive. NPs
coated with heparin (NP@heparin) are extensively studied
because of their several biomedical applications ranging from
tissue engineering to biosensors passing for its use in cancer
therapy [3]. As well as heparin, also chitosan NPs have
demonstrated anticancer activity in vitro as well as in vivo
even though the mechanisms remain to be elucidated [18].
In this paper, we have reported cytotoxicity and uptake
of some transition metal oxide NPs (Co3O4, Fe3O4, and
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Figure 1: Chemical structure of chitosan (A) and carboxymethyl-
chitosan (B).
NiO) coated with heparin and of Fe3O4NPs coated with
CMCS (Fe3O4@CMCS) in SKOV-3 cell. Transition metal
NPs are especially used to enhance surface electrochemical
reactivity to further improve the performance of lithium-ion
batteries [19] as well as in catalysis [20, 21]. Nevertheless, the
therapeutic use of transition metal conjugates was already
known in the sixteenth century because of their diferent
oxidation states and ability to interact with negatively charged
molecules forming chelation complexes [22].
he results here reported indicate that heparin andCMCS
alone did not show any cytotoxicity efect at the concentration
used in the experiments. Unfortunately, they did not seem to
be able to drastically reduce NP toxicity.
2. Materials and Methods
2.1. Chemicals. Iron oxide (Fe3O4), cobalt oxide (Co3O4)
and nickel oxide (NiO) NPs (<50 nm particle size), chitosan
powder (75% degree of acetylation), monochloroacetic acid,
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochlo-
ride (EDC⋅HCl), and N-hydroxysuccinimide (NHS) were
purchased from Sigma-Aldrich, Milan, Italy. Heparin, in
the form of sodium salt, was kindly provided by LDO
Company, Trino Vercellese, Italy. CellTiter-Glo Luminescent
Cell Viability Assay was purchased from Promega, Milan,
Italy. Isopropanol was purchased from J.T.Baker, Milan, Italy.
All other reagents, analytical or cell culture grade, were
purchased from Sigma-Aldrich, Milan, Italy. he Milli-Q
ultrapure water was used.
2.2. Nanoparticles Characterization. he particle size dis-
tribution was studied by transmission electron microscopy
(TEM) using a 90 keV JEOL-1010 electron microscope
(Tokyo, Japan). TEM samples were prepared by placing 10�L
of a dilute suspension of Fe3O4 nanoparticles in ethanol
on a carbon-coated copper grid and allowing the solvent
to evaporate at room temperature. he average particle size
(�TEM) and distribution were evaluated by measuring the
largest internal dimension of 100 particles.
2.3. Synthesis of Carboxymethylchitosan (CMCS). CMCS was
prepared as reported by Zhu et al. [23]. he chemical
structures of chitosan and CMCS are reported in Figure 1.
2.4. Coating of Metal Nanoparticles
2.4.1. NP@heparin. A suspension of NPs (Co3O4 or Fe3O4 or
NiO) in distilled water (100mg/5mL) obtained by ultrason-
ication for 5min (Sonica 5300MH-Soltec) was transferred
into a solution of heparin, (1.045 g/25mL, pH 7 adjusted with
0.01N NaOH). he mixture was stirred overnight (130 rpm,
25∘C, Julabo SW22). Co3O4@heparin and NiO@heparin
were separated by centrifugation (1 h, 6300×g, Hettich
Zentrifugen-Rotina 35 F), while Fe3O4@heparin was sepa-
rated by a neodymium magnet (NdFeB Nickel plated, mag-
netization N45). NP@heparin were collected in diethyl ether,
recovered ater solvent elimination and dried at 50∘C for
1 h.
2.4.2. Fe3O4@CMCS Electrostatic Bound. A suspension of
100mgof Fe3O4NPs in 5mLwaterwas prepared by ultrasonic
bath for 10min. Separately, 100mg of CMCS was dissolved
in 20mL of water using a magnetic stirrer until complete
dissolution, then added to the Fe3O4 NPs dispersion and
mixed by ultrasonic bath at 0∘C for 1 h. Ater reaction, the
Fe3O4@CMCS was separated from unbound CMCS by a
neodymium magnet, washed several times with water, and
centrifuged at 15000×g, 20min. he pellet was resuspended
in ethyl alcohol then, ater anhydriication, Fe3O4@CMCS
was dried overnight at 50∘C.
2.4.3. Fe3O4@CMCS-Covalent Bound. he covalent immo-
bilization of CMCS on Fe3O4NPs was conducted following
Liang and Zhang method [24] with some modiications.
Briely, 75mg of Fe3O4NPs were added to 4mL of sodium
phosphate bufer (200mM, pH 5) containing 25mg of
EDC⋅HCl and 20mg of NHS; the mixture was let in an
ultrasonic bath for 30min. he Fe3O4NPs activated were
separated from excess of reagents by magnetic decantation,
then resuspended in 3mL of 200mM sodium phosphate
bufer (pH 7) by sonication for 10min. 1mL of CMCS
solution (25mg/mL in 200mM sodium phosphate bufer, pH
7) was added to the suspension of the NPs and the reaction
mixture was sonicated for 3 h. Finally, the Fe3O4@CMCS was
recovered bymagnet, washedwith water, and dried overnight
at 50∘C.
2.4.4. Determination of Unbound Fe. 5mg of Fe3O4NPs, or
Fe3O4@heparin, or Fe3O4@CMCS electrostatically bound or
Fe3O4@CMCS covalently bound were resuspended in 5mL
of H2O, sonicated for 20min, and let at 37
∘C for 72 h.
Aterwards, NP systems were separated from the supernatant
by a neodymium magnet, centrifuged twice at 15000×g
for 15min at 4∘C, then ultracentrifuged at 300000×g for
2 h at 4∘C. Ater centrifugation, supernatants were iltered
using a 0.22�m pore size membrane. he amount of Fe
(II), eventually released in solution, was determined by
complexometric analysis with the o-phenanthroline [25].he
Fe (II), in the presence of o-phenanthroline, form the stable
red-orange complex [(C12H18N2)3Fe]
2+. he intensity of the
color does not vary in the range of pH between 3 and 9.
he maximum absorption wavelength occurs at 510 nm. he
possible Fe (III) is reduced to Fe (II) by treatment with
hydroxylamine hydrochloride.
2.5. FT-IR Spectra Analysis. Characterization of the samples
was performed using the solid phase Fourier transform
infrared spectroscopy (FT-IR). Spectra were obtained using a
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Nicolet, Avatar 360. Samples were mixed with infrared grade
KBr in a proportion of 2 : 100 (w/w).
2.6. Cell Culture. SKOV-3 cell line was maintained as adher-
ent cells in RPMI 1640 medium, at 37∘C in a humidiied 5%
CO2 atmosphere. Medium was supplemented with 10% fetal
bovine serum and 2mM L-glutamine. Cells were passaged as
needed using 0.5% trypsin EDTA.
2.7. Cell Viability. Cell viability was determined measuring
ATP content by the CellTiter-Glo Assay according to the
manufacturer’s instructions. In details, 200�L of cell suspen-
sion (containing 2 × 104, 1 × 104, 5 × 103, 25 × 102 cells
depending of the exposure time) were seeded into 96-well
assay plates and cultivated for 24 h at 37∘C in 5% CO2 to
equilibrate and become attached prior to the treatment.hen,
cells were exposed to 100�L of increasing concentrations of
heparin, NP@heparin, CMCS, Fe3O4@CMCS electrostatic,
and Fe3O4@CMCS covalent for 0.5, 1, 2, 24, 48, and 72 h.
Ater the treatment, plates were equilibrated for 30min at
room temperature and then 100 �L of CellTiter-Glo reagent
was added to each well. Plates were shaken for 2min and let
at room temperature for 10min prior recording luminescent
signals using the Ininite F200 plate reader (Tecan Group,
Switzerland). Cell viability, expressed as ATP content and
normalized against control values, was recorded. All the
experiments were performed in triplicate.
2.8. Cellular Uptake. 104 cells were seeded on a coverslip
(12mm Ø) into 12-well assay plate and cultivated for 24 h
at 37∘C in 5% CO2 to equilibrate and become attached
before treatment. Cells were then incubated for 4 or 24 h
with 25, 50, and 100 �g/mL Fe3O4@heparin, Fe3O4@CMCS
electrostatic, and Fe3O4@CMCS covalent and visualized by
Prussian blue staining for iron detection. For thismicroscopic
technique, the cells were ixed in ice-cold ethanol for 5min,
stained with an equal volume of 2% hydrochloric acid and
2% potassium ferrocyanide trihydrate for 15min, and coun-
terstained with 0.5% neutral red for 3min. he preparations
were thenwashedwith distilled water and dried by increasing
concentrations of ethanol, than mounted in DePeX (Serva,
Germany).Observationswere performed by aZeissAxiophot
microscope under bright light illumination and photographs
were acquired by a Zeiss AxioCam ERc5s camera.
Furthermore, for TEM studies, 106 cells, seeded in a
10 cm Petri dish, are exposed to 40�g/mL of NP@heparin,
Fe3O4@CMCS electrostatic, and Fe3O4@CMCS covalent,
for 30min or 3 h. hen cells were harvested, ixed in 2%
glutaraldehyde in 0.1M sodium cacodylate bufer (pH 7.2) for
10min on ice and for 30min at room temperature, washed in
the same bufer, and postixed in dark for 1 h with 1% osmium
tetroxide in 0.1M sodium-cacodylate bufer (pH 7.2) at room
temperature. Ater dehydration standard steps with a series
ethyl alcohol, samples were embedded in an Epon-Araldite
812 1 : 1 mixture. hin sections (90 nm), obtained with a
ReichertUltracut S Ultratome (Leica, Nussloch, Germany),
were stained with uranyl acetate and lead citrate according to
the standard methods and observed with a Jeol 1010 electron
microscope (Jeol, Tokyo, Japan) operated at 90 keV.
591
500100015002000250030003500
40
50
60
70
80
90
100
1612
814
1225
A
B
�
(%
)
Wavenumbers (cm−1)
Figure 2: FT-IR spectra of Fe3O4NPs (A) and Fe3O4@heparin (B).
he peaks at 814 cm−1, between 1000 and 1400 cm−1 and those at
1225, and 1612 cm−1 are indicative of the heparin coating.
2.9. Statistical Analysis. Cell viability values were expressed
as mean ± standard error (SE). Analysis of variance (two-way
ANOVA), for balanced mixed-efect experiments (uncoated
NPs, coated NPs, and exposure times), was performed using
KaleidaGraph 4.0 (Synergy Sotware). Statistical signiicant
diferences were ixed at � ≤ 0.05 (∗), � ≤ 0.01 (∗∗), and
� ≤ 0.005 (∗∗∗).
3. Results
3.1. Nanoparticles Characterization. To conirm the charac-
teristics reported on the product label by Sigma-Aldrich,
we have measured Fe3O4NPs diameter. �TEM was 25.08 nm
± SD 4.09. he amount of Fe released from Fe3O4NPs,
or Fe3O4@heparin, or Fe3O4@CMCS-electrostatic bound or
Fe3O4@CMCS-covalent bound, in our experimental con-
ditions, was under the limit of detection of the method
(0.02 ppm).
3.2. FT-IR Spectra Analysis. In Figure 2, we have reported,
as example, the FT-IR spectra of Fe3O4NPs (A) and
Fe3O4@heparin (B). Spectrum (B) shows, at 591 cm
−1, the
characteristic peak of Fe–O stretch, while, between 1000 and
1400 cm−1, peaks associated to C–O and C–C bonds due to
the presence of heparin are present. Other peaks at 814, 1225,
and 1612 cm−1 can be assigned to the stretching of –C–O–S, –
S=O, and –COO− of the sulphates and carboxylate groups.
Lambda shits toward lower values compared to heparin
alone are probably ascribable to the interaction with iron
oxide.
FT-IR spectra of chitosan (A) andCMCS (B) are shown in
Figure 3. Spectrum A shows the basic characteristic peaks of
chitosan: 3550 cm−1 (O–H stretch), 2930 cm−1 (C–H stretch),
1648 cm−1 (NH bending), 1405 cm−1 (O–H bending), and
1080 cm−1 (C–O stretch). In addition to the peaks at 3550,
2930, 1405, and 1080 cm−1, CMCS spectrum (B) reports an
expanded and intense peak at 1612 cm−1 probably due to the
overlapping of the signals of NH bending (1648 cm−1) and
COO− (1598 cm−1) [23].
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Figure 3: FT-IR spectra chitosan (A) and CMCS (B). Chemical
modiication of chitosan is conirmed by the presence of the intense
peak at 1612 cm−1, attributed to the overlapping of the signals of NH
bending and –COO−.
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Figure 4: FT-IR spectra Fe3O4NPs (A) and Fe3O4@CMCS (B). he
peaks at 1067, 1406, 1608, and 3550 cm−1 indicate the presence of
CMCS on the Fe3O4NPs surface.
Fe3O4NPs (A) and Fe3O4@CMCS (B) spectra are shown
in Figure 4. In spectrum A, the peak at 561 cm−1 is that
characteristic of Fe–O stretch. Spectrum B, beside to the
peak at 561 cm−1, reports the absorbance of CMCS molecule,
in particular 1067 cm−1 (C–O stretch), 1406 cm−1 (O–H
bend), 1608 cm−1 (overlapping of the peaks of NH2, COOH,
and COO−), and 3550 cm−1 (O–H stretch). No signiicant
diferences were observed between spectra of Fe3O4@CMCS
electrostatically and covalently bound.
3.3. Cell Viability ater NP@heparin Treatment. As reported
in Figure 5(a), heparin alone was not toxic in the examined
concentration range. A dose- and time-dependent reduction
in cell viability was observed for all the examinedNP systems,
although Fe3O4NPs appear less toxic than Co3O4 NPs which
is less toxic than NiO NPs, see Figures 6(a), 7(a), and 8(a).
Regarding the comparison between uncoated and coated
NPs, our data indicate that the coating did not decrease the
NPs toxicity. As demonstrated in Figure 6, Co3O4NPs were
less toxic than Co3O4@heparin for all the examined con-
centrations and time of treatment. he diferences were less
indicative for Fe3O4NPs and NiO NPs (Figures 7 and 8). For
further details, see Supplementary Material Tables 1, 2, and 3
available online at http://dx.doi.org/10.1155/2013/314091.
3.4. Cell Viability ater Fe3O4@CMCS Treatment. he ATP
content of SKOV-3 treated with Fe3O4NPs, Fe3O4@CMCS-
electrostatic, and Fe3O4@CMCS covalent are displayed in
Figure 9. he percentage of CMCS bound to NPs was less
than 4% of the total weight; therefore, it was reasonable
to compare the amount of coated and uncoated Fe3O4NPs
neglecting the weight of CMCS bound. As previously
reported (Figure 5(b)), CMCS itself did not show cytotoxicity
at the tested concentrations. On the contrary, Fe3O4@CMCS
covalent, and electrostatic, caused a dose-dependent reduc-
tion of ATP (Figures 9(a), 9(b) and 9(c)) more pronounced
compared to the bare Fe3O4NPs. For further details see
Supplementary Material Table 4.
3.5. Cellular Uptake. Figures 10(a)–10(d) show the uptake
of coated Fe3O4NPs by using the classical Prussian blue
method. he cytoplasm is full of NPs around the nucleus but
never inside. Fe3O4@heparin (Figure 10(d)) are more inter-
nalized compared to Fe3O4@CMCS covalent (Figure 10(b))
and electrostatic (Figure 10(c)). Apparently, no diferences
are observed between the two chitosan systems. Coated
Fe3O4NPs are readily incorporated into the cells already ater
4 h; therefore, it is not possible to assert a time and dose
dependence. In addition, for all the NP systems, it is observed
that internalized NP did not interfere with mitosis process
(Figures 10(b)–10(d)).
TEM images (Figure 11) conirmed that NP@heparin are
readily internalized; in fact, already ater 30min of incubation
NPs appeared inside the cells. Once entered most of the NPs
remained in the cytoplasm, free or inside vesicles (Figures
11(a)–11(c)). As already highlighted by optical microscope,
besides being rapid, internalization of the nanoparticles was
aspeciic. In these pictures, NP@heparin are identiied as high
electron density objects since NPs maintained the morphol-
ogy observed in cell-free environment (Figure 11(d)). Worth
to note is that, also ater 3 h of exposure, no NP@heparin was
observed in the nuclei even though the massive internaliza-
tion of NPs can modify nucleus shape (Figure 12).
From our observations, the internalization did not seem
to be inluenced by the coating. Our hypothesis is conirmed
by TEM picture (Figure 13) that did not show appreciable
diferences in cellular localization between Fe3O4@CMCS
electrostatically or covalently bound and NP@heparin (Fig-
ures 11 and 12).
4. Discussion
In recent years, the use of NPs, particularly MNPs, has
expanded into biomedical research. Due to their unique
properties such as small size, large surface area, and high
reactivity, they are particularly suitable for diagnosis and
therapy [1, 26–29]. Oten, NPs have to be covered with
molecules to get a core@shell system capable to bind bioactive
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Heparin
0
20
40
60
80
100
120
0 20 40 60 80 100 120 140 160
A
T
P
 c
o
n
te
n
t 
(%
)
30′
60′
120′
(휇g)
24h
48h
72h
(a)
0
20
40
60
80
100
120
0 20 40 60 80 100 120 140 160
A
T
P
 c
o
n
te
n
t 
(%
)
CMCS
30′
60′
120′
(휇g)
24h
48h
72h
(b)
Figure 5: Percentage of ATP content, normalized to control, in SKOV-3 exposed to heparin (a) and carboxymethylchitosan (b) for diferent
times.
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Figure 6: Percentage of ATP content, normalized to control, in SKOV-3 exposed to Co3O4NPs (a) and Co3O4@heparin (b) for diferent
times.
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Figure 7: Percentage of ATP content, normalized to control, in SKOV-3 exposed to Fe3O4NPs (a) and Fe3O4@heparin (b) for diferent times.
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Figure 8: Percentage of ATP content, normalized to control, in SKOV-3 exposed to NiO NPs (a) and NiO@heparin (b) for diferent times.
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Figure 9: Percentage of ATP content, normalized to control, in SKOV-3 exposed to Fe3O4NPs (a), Fe3O4@CMCS electrostatic (b), and
Fe3O4@CMCS covalent (c) for diferent times.
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Figure 10: Uptake of SKOV-3 cells ater 24 h of incubation with 25mg/mL of anionic NPs. (a) Control cells; (b) Fe3O4@CMCS covalent;
(c) Fe3O4@CMCS electrostatic; (d) Fe3O4@heparin. As shown in (b, c, and d) internalized NPs did not interfere with mitosis process.
Magniication: 40x.
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Figure 11: TEM pictures of SKOV-3 cells exposed to Co3O4@heparin (a), Fe3O4@heparin (b), and NiO@heparin (c) for 30min. (d) A picture
of Fe3O4@heparin deposited on a formvar carbon coated grid.
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Figure 12: TEM picture showing a large agglomerate of
Co3O4@heparin which modiies the shape of a SKOV-3 nucleus.
Cells were ixed ater 30min of exposure.
molecules, stable in physiological luids and possibly not
toxic to the body. Among the innumerable coating materials,
polymers such as heparin, dextran, carboxydextran, chitosan,
and polyethylene glycol are consideredmore advantageous to
satisfy the above-mentioned characteristics [30–33].
In particular, the literature reports several applications
of NPs covered with heparin, ranging from use as imaging
agent to apoptosis-induced agent in cancer cell, as well as
components of nanodevices [34–36].Unfortunately, thiswide
number of publications does not include toxicity studies of
the synthesized systems. In particular, the literature lacks
data on the comparison between the toxicity of core and
core@shell. To try to ill this gap, in our laboratory, we have
studied the characteristics and behavior of Co3O4, Fe3O4, and
NiO NPs covered with heparin.
From our experiments resulted that the coating had
signiicantly increased the colloid stability and hydrophilic
property of metal NPs. In fact, the systems NP@heparin
did not agglomerated thanks to the presence of negatively
charged groups around the metallic core. he experiments
on cytotoxicity, performed on SKOV-3 cells, have shown
that heparin itself was not toxic within the range of the
examined concentrations (see Figure 5(a)). Furthermore, as
expected, Fe3O4@heparin was the less toxic system, while
NiO@heparin was the most toxic one. Contrary to what
one would expect, NP@heparin had not been found less
toxic compared to the naked NPs for all the examined
metals (see Figures 6, 7, and 8). Depletion of ATP content,
observed in these experiments, could be due to the massive
internalization of NP@heparin by the cells, phenomenon
substantiated by Prussian blue staining for iron detection.
Nevertheless, at the concentrations used in these experi-
ments, internalized Fe3O4@heparin did not arrest mitosis
process and nanoparticles were shared between the daughter
cells. Further analysis by TEM have demonstrated that
NP@heparin were already present inside the cell ater 30 min
of exposure (Figures 11(a), 11(b), and 11(c)). In this work, we
have not investigated the mechanisms of internalization even
though, as shown in Figures 11(a), 11(b), and 11(c) and as
reported by the literature [37–39], endocytosis is certainly a
possible way. Notwithstanding in our previous work we had
observed the presence of NPs also in the mitochondria and
in the nuclei [40], in these experiments NPs were conined
(a)
(b)
Figure 13: TEM pictures of SKOV-3 cells exposed for 30min to
Fe3O4@CMCS electrostatic (a) and covalent (b).
only in cytoplasmic vesicles, even though, sometimes, the
vesicle size was so enormous to modify nuclear shape and/or
cause mechanical damages to the cell (see Figure 12). When
the endocitotic vesicles had sizes that did not justify the
mechanical damage, we could assume that cell toxicity could
be due to the release of metal ions by the NP system; this
hypothesis was supported by the data of cell viability in which
Fe3O4 NPs resulted the least toxic metal.
Chitosan, but even better CMCS, preferred because the
carboxymethylation increases the chitosan solubility in phys-
iological luids, is widely studied for theranostic applications
[41, 42]. Despite the Prussian blue staining indicated that
Fe3O4@chitosan uptake was less eicient compared to that
of Fe3O4@heparin, TEM analysis showed that no diferences
were noticeable between the two NP systems. Furthermore,
as previously reported for heparin, the presence of negative
charges on NP surface enhances interactions with the cell
membrane facilitating cellular uptake [6, 38]. hanks to
its biocompatibility and the presence of active functional
groups (amino, carboxyl, and hydroxyl), CMCS is a valid
instrument to design novel biocompatible materials with
tailored chemical and biophysical properties [43–46].Despite
the wide use of CMCS little or nothing is known about its
behavior when it is associated with metal NPs. his lack of
data suggested us to evaluate the properties and the potential
toxicity of the system Fe3O4@CMCS itself and compared
to the naked Fe3O4NPs. For our studies, we have set up
two diferent systems: Fe3O4@CMCS-electrostatic bound
and Fe3O4@CMCS-covalent bound. he interest in coating
Fe3O4NPs by covalent bond resided in an attempt to get a sys-
tem characterized by a more stable shell in hydrophilic luids.
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Our studies on cell viability conirmed the biocompati-
bility of free CMCS at the tested conditions. When cells are
exposed to Fe3O4@CMCS electrostatic, viability decreases
with the same trend of Fe3O4NPs treatment (Figures 9(a)
and 9(b)). he higher toxicity observed for Fe3O4@CMCS-
covalent bond (Figure 9(c)) suggested that the method of
preparation of the NPs could inluence the cellular response.
Also in this case, uptake by SKOV-3 cells was relevant
showing massive internalization already ater 30min
with NPs stored in cytoplasmic vesicles (Figure 13)
with no detectable diference between NP@heparin and
Fe3O4@CMCS.
Our results have conirmed the data present in the
literature about the biocompatibility of heparin and CMCS
and their capability to get stable suspensions in hydrophilic
luids when conjugated to metal NPs, but not the ability
to reduce the cytotoxicity of metal NPs coated with these
polymers. Nevertheless, it is diicult to compare data derived
from diferent experimental conditions such as diferent
concentration ranges rather than diverse cell types which
can give diverse responses to the same treatment [2, 47].
Moreover, the published data are oten related to the whole
system prepared and not to the single component, as we did,
then the comparison is very diicult if not impossible.
In conclusion, the reactive groups, present on the surface
of core@shell systems that we have synthesized, provide the
opportunity for further functionalization so that a variety
of biomolecules may be immobilized to enhance speciic
cell recognition for their use in targeting studies. Moreover,
as regards Fe3O4NPs, even though the coating does not
reduce their toxicity, the amount of NPs present in the sys-
tems is usually so low to render their toxicity negligible.
Furthermore, due to their magnetic properties, Fe3O4NPs
can be directed to the site of interest thanks to an external
magnet. From this point of view, they could be promising
tools as drug carrier for diagnosis and therapy.
Conflict of Interests
No conlict of interests is present. he authors have no inan-
cial involvement or interest with any organization or com-
pany about subjects or materials discussed in the paper.
Acknowledgments
A. Bava was supported by Consorzio Interuniversitario Bio-
tecnologie and by Associazione Amici dell’Universita` grants.
References
[1] A. G. Cattaneo, R. Gornati, E. Sabbioni et al., “Nanotechnology
and human health: risks and beneits,” Journal of Applied Toxi-
cology, vol. 30, no. 8, pp. 730–744, 2010.
[2] H. Eidi, O. Joubert, G. Attik et al., “Cytotoxicity assessment of
heparin nanoparticles in NR8383 macrophages,” International
Journal of Pharmaceutics, vol. 396, no. 1-2, pp. 156–165, 2010.
[3] M. M. Kemp and R. J. Linhardt, “Heparin-based nanoparti-
cles,”Wiley Interdisciplinary Reviews: Nanomedicine and Nano-
biotechnology, vol. 2, no. 1, pp. 77–87, 2010.
[4] V. K. Mourya, N. N. Inamdar, and A. Tiwari, “Carboxymethyl
chitosan and its applications,”AdvancedMaterials Letters, vol. 1,
no. 1, pp. 11–33, 2010.
[5] R. Riva, H. Ragelle, A. des Rieux, N. Duhem, C. Je´roˆme, and V.
Pre´at, “Chitosan and chitosan derivatives in drug delivery and
tissue engineering,” Advances in Polymer Science, vol. 244, pp.
19–44, 2011.
[6] A. Zhu, L. Yuan, and T. Liao, “Suspension of Fe3O4 nanoparti-
cles stabilized by chitosan and o-carboxymethylchitosan,” Inter-
national Journal of Pharmaceutics, vol. 350, no. 1-2, pp. 361–368,
2008.
[7] H. Y. Hwang, I. S. Kim, I. C. Kwon, and Y. H. Kim, “Tumor tar-
getability and antitumor efect of docetaxel-loaded hydropho-
bically modiied glycol chitosan nanoparticles,” Journal of Con-
trolled Release, vol. 128, no. 1, pp. 23–31, 2008.
[8] R. Dinarvand, N. Sepehri, S. Manoochehri, H. Rouhani,
and F. Atyabi, “Polylactide-co-glycolide nanoparticles for con-
trolled delivery of anticancer agents,” International Journal of
Nanomedicine, vol. 6, pp. 877–895, 2011.
[9] C. E. Mora-Huertas, H. Fessi, and A. Elaissari, “Polymer-
based nanocapsules for drug delivery,” International Journal of
Pharmaceutics, vol. 385, no. 1-2, pp. 113–142, 2010.
[10] A. Bava, R. Gornati, F. Cappellini, L. Caldinelli, L. Pollegioni,
andG. Bernardini, “D-amino acid oxidase-nanoparticle system:
a potential novel approach for cancer enzymatic therapy,”
Nanomedicine, 2013.
[11] A. Nel, T. Xia, L.Ma¨dler, andN. Li, “Toxic potential of materials
at the nanolevel,” Science, vol. 311, no. 5761, pp. 622–627, 2006.
[12] S. Singh and H. S. Nalwa, “Nanotechnology and health safety
- Toxicity and risk assessments of nanostructured materials on
human health,” Journal of Nanoscience and Nanotechnology, vol.
7, no. 9, pp. 3048–3070, 2007.
[13] E. Papis, R. Gornati, J. Ponti, M. Prati, E. Sabbioni, and G.
Bernardini, “Gene expression in nanotoxicology: a search for
biomarkers of exposure to cobalt particles and ions,” Nanotoxi-
cology, vol. 1, no. 3, pp. 198–203, 2007.
[14] E. Papis, R. Gornati, M. Prati, J. Ponti, E. Sabbioni, and
G. Bernardini, “Gene expression in nanotoxicology research:
analysis by diferential display in BALB3T3 ibroblasts exposed
to cobalt particles and ions,” Toxicology Letters, vol. 170, no. 3,
pp. 185–192, 2007.
[15] M. Di Gioacchino, N. Verna, L. Di Giampaolo et al., “Immuno-
toxicity and sensitizing capacity of metal compounds depend
on speciation,” International Journal of Immunopathology and
Pharmacology, vol. 20, no. 2, pp. 15–22, 2007.
[16] A.Munoz andM. Costa, “Elucidating themechanisms of nickel
compound uptake: a review of particulate and nano-nickel
endocytosis and toxicity,”Toxicology andApplied Pharmacology,
vol. 260, pp. 1–16, 2012.
[17] A. G. . Cattaneo, R. Gornati, M. Chiriva-Internati, and G.
Bernardini, “Ecotoxicology of nanomaterials: the role of inver-
tebrate testing,” Invertebrate Survival Journal, vol. 6, pp. 78–97,
2009.
[18] Y. Xu, Z. Wen, and Z. Xu, “Chitosan nanoparticles inhibit the
growth of human hepatocellular carcinoma xenograts through
an antiangiogenic mechanism,”Anticancer Research, vol. 29, no.
12, pp. 5103–5109, 2009.
[19] P. Poizot, S. Laruelle, S. Grugeon, L. Dupont, and J. M. Taras-
con, “Nano-sized transition-metal oxides as negative-electrode
materials for lithium-ion batteries,” Nature, vol. 407, no. 6803,
pp. 496–499, 2000.
10 BioMed Research International
[20] L. D. Pacho´n and G. Rothenberg, “Transition-metal nanopar-
ticles: synthesis, stability and the leaching issue,” Applied
Organometallic Chemistry, vol. 22, no. 6, pp. 288–299, 2008.
[21] M. Moreno-Man˜as and R. Pleixats, “Formation of carbon-
carbon bonds under catalysis by transition-metal nanoparti-
cles,” Accounts of Chemical Research, vol. 36, no. 8, pp. 638–643,
2003.
[22] S. Raique, M. Idrees, A. Nasim, H. Akbar, and A. Athar,
“Transition metal complexes as potential therapeutic agents,”
Biotechnology and Molecular Biology Reviews, vol. 5, no. 2, pp.
38–45, 2010.
[23] A. Zhu, M. B. Chan-Park, S. Dai, and L. Li, “he aggregation
behavior of O-carboxymethylchitosan in dilute aqueous solu-
tion,” Colloids and Surfaces B, vol. 43, no. 3-4, pp. 143–149, 2005.
[24] Y. Y. Liang and L. M. Zhang, “Bioconjugation of papain on
superparamagnetic nanoparticles decorated with carboxyme-
thylated chitosan,” Biomacromolecules, vol. 8, no. 5, pp. 1480–
1486, 2007.
[25] D. R. Kester, I.W.Duedall, D. N. Connors, and R.M. Pytkowicz,
“Preparation of artiicial sea water,” Limnology and Oceanogra-
phy, vol. 12, no. 1, pp. 176–179, 1967.
[26] R. Bhattacharya and P. Mukherjee, “Biological properties of
”naked” metal nanoparticles,”Advanced Drug Delivery Reviews,
vol. 60, no. 11, pp. 1289–1306, 2008.
[27] J. Conde, G. Doria, and P. Baptista, “Noble metal nanoparticles
applications in cancer,” Journal of Drug Delivery, vol. 2012,
Article ID 751075, 12 pages, 2012.
[28] J. L.Martinez-Hurtado, “Metallic nanoparticle block copolymer
vesicles with enhanced optical properties,” Nanomaterials, vol.
1, pp. 20–30, 2011.
[29] P. Tartaj, M. Del Puerto Morales, S. Veintemillas-Verdaguer, T.
Gonza´lez-Carren˜o, and C. J. Serna, “he preparation of mag-
netic nanoparticles for applications in biomedicine,” Journal of
Physics D, vol. 36, no. 13, pp. R182–R197, 2003.
[30] M. M. Kemp, A. Kumar, S. Mousa et al., “Synthesis of gold and
silver nanoparticles stabilized with glycosaminoglycans having
distinctive biological activities,” Biomacromolecules, vol. 10, no.
3, pp. 589–595, 2009.
[31] H. Khurshid, S. H. Kim, M. J. Bonder et al., “Development
of heparin-coated magnetic nanoparticles for targeted drug
delivery applications,” Journal of Applied Physics, vol. 105, no.
7, Article ID 07B308, 3 pages, 2009.
[32] C. Sun, J. S. H. Lee, and M. Zhang, “Magnetic nanoparticles
in MR imaging and drug delivery,” Advanced Drug Delivery
Reviews, vol. 60, no. 11, pp. 1252–1265, 2008.
[33] O.Veiseh, J.W.Gunn, andM. Zhang, “Design and fabrication of
magnetic nanoparticles for targeted drug delivery and imaging,”
Advanced Drug Delivery Reviews, vol. 62, no. 3, pp. 284–304,
2010.
[34] D. Y. Lee, “Highly efective T2MR contrast agent based on hep-
arinized superparamagnetic iron oxide nanoparticles,” Macro-
molecular Research, vol. 19, no. 8, pp. 843–847, 2011.
[35] K. Lee, H. Lee, K. H. Bae, and T. G. Park, “Heparin immobilized
gold nanoparticles for targeted detection and apoptotic death of
metastatic cancer cells,” Biomaterials, vol. 31, no. 25, pp. 6530–
6536, 2010.
[36] K. A. Min, F. Yu, V. C. Yang, X. Zhang, and G. R. Rosania,
“Transcellular transport of heparin-coated magnetic iron oxide
nanoparticles (Hep-MION) under the inluence of an applied
magnetic ield,” Pharmaceutics, vol. 2, no. 2, pp. 119–135, 2010.
[37] A. Villanueva, M. Ca˜ete, A. G. Roca et al., “he inluence of
surface functionalization on the enhanced internalization of
magnetic nanoparticles in cancer cells,”Nanotechnology, vol. 20,
no. 11, Article ID 115103, 9 pages, 2009.
[38] E. Sabbioni, S. Fortaner, M. Farina et al., “Interaction with cul-
ture medium components, cellular uptake and intracellular
distribution of cobalt nanoparticles, microparticles and ions in
Balb/3T3 mouse ibroblasts,” Nanotoxicology, 2012.
[39] C.Wilhelm and F. Gazeau, “Universal cell labelling with anionic
magnetic nanoparticles,” Biomaterials, vol. 29, no. 22, pp. 3161–
3174, 2008.
[40] E. Papis, F. Rossi, M. Raspanti et al., “Engineered cobalt oxide
nanoparticles readily enter cells,” Toxicology Letters, vol. 189, no.
3, pp. 253–259, 2009.
[41] H. Arami, Z. Stephen, O. Veiseh, and M. Zhang, “Chitosan-
coated iron oxide nanoparticles formolecular imaging and drug
delivery,”Advances in Polymer Science, vol. 243, pp. 63–184, 2011.
[42] X. G. Chen and H. J. Park, “Chemical characteristics of O-
carboxymethyl chitosans related to the preparation conditions,”
Carbohydrate Polymers, vol. 53, no. 4, pp. 355–359, 2003.
[43] A. P. Zhu, N. Fang, M. B. Chan-Park, and V. Chan, “Interac-
tion between O-carboxymethylchitosan and dipalmitoyl-sn-
glycero-3- phosphocholine bilayer,”Biomaterials, vol. 26, no. 34,
pp. 6873–6879, 2005.
[44] P. Agrawal, G. J. Strijkers, and K. Nicolay, “Chitosan-based sys-
tems for molecular imaging,” Advanced Drug Delivery Reviews,
vol. 62, no. 1, pp. 42–58, 2010.
[45] D. Bhattacharya, M. Das, D. Mishra et al., “Folate receptor
targeted, carboxymethyl chitosan functionalized iron oxide
nanoparticles: a novel ultradispersed nanoconjugates for bi-
modal imaging,” Nanoscale, vol. 3, no. 4, pp. 1653–1662, 2011.
[46] T. T. Trang Mai, P. T. Ha, H. N. Pham et al., “Chitosan and
O-carboxymethylchitosan modiied Fe3O4 for hyperthermic
treatment,” Advances in Natural Sciences: Nanoscience and
Nanotechnology, vol. 3, Article ID 015006, 5 pages, 2012.
[47] C. F. Jones and D. W. Grainger, “In vitro assessments of nano-
material toxicity,” Advanced Drug Delivery Reviews, vol. 61, no.
6, pp. 438–456, 2009.
